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Abstract 
Distal diabetic peripheral polyneuropathy (DPN) is a prevalent complication 
resulting from chronic hyperglycemia in diabetic patients.  It is associated with 
incapacitating pain, foot ulceration, and lower-limb amputations and brings about 
physical and psychological burdens to a patient’s quality of life and a large economic 
burden to the health care system.  Despite the prevalence and severity of DPN, the 
development of therapies that have focused on “diabetes specific” targets has met with 
limited translational success.  This is due, at least in part, to the fact that disease 
progression among individuals does not occur with temporal and/or biochemical 
uniformity.  Thus, our innovative approach has explored the premise that it is not 
necessary to target a specific pathogenic mechanism to reverse DPN and that 
pharmacologic induction of cytoprotective molecular chaperones affords a novel 
mechanism to improve myelinated and unmyelinated fiber function in DPN.  To this end, 
we established that KU-32, a novel, non-toxic small molecule inhibitor of the molecular 
chaperone heat shock protein 90 (Hsp90) was able to protect sensory neurons from 
glucotoxicity and decrease the symptoms of DPN in diabetic mice.  However, despite 
KU-32’s efficacy in improving the sensory deficits of DPN in diabetic mice, specific 
mechanisms of neuroprotection remain unidentified.  Thus, this dissertation utilized 
variations of stable isotope labeling with amino acids in cell culture (SILAC) as a novel, 
unbiased and systematic approach to quantitatively study the effect of hyperglycemia and 
KU-32 on the mitochondrial proteomes from dorsal root ganglia (DRG) neurons and 
Schwann cells (SCs) as in vitro models of DPN.   
 
 
III 
This dissertation provides the first quantitative characterization of the temporal 
effect of hyperglycemia on the SC proteome using SILAC.  Specifically, hyperglycemia 
increased the expression of numerous mitochondrial proteins in SCs that regulate 
oxidative phosphorylation and anti-oxidant responses.  Consistent with these 
observations, hyperglycemia did not induce superoxide production in SCs and this 
correlated with an increase in MnSOD and the extent of proton leak, which may function 
in reducing oxidative stress.  Although hyperglycemia increased mitochondrial 
respiration, the increase in proton leak suggests that respiration is less efficient at 
producing ATP.  However, this deficiency may be offset by the ability of hyperglycemia 
to increase glycolysis in SCs.  In contrast, hyperglycemia decreased mitochondrial 
respiratory capacity in DRG sensory neurons and promoted a robust induction in 
superoxide production.  Treatment of KU-32 antagonized the effect of hyperglycemia by 
decreasing mitochondrial superoxide levels and improving organellar bioenergetics in 
DRG neurons.  These functional improvements correlated with the translational induction 
of MnSOD and mitochondrial chaperones by KU-32.  Overall, studies in this dissertation 
provide evidence that sensory neurons and SCs have rather distinct energetic responses to 
hyperglycemia and that SCs can more effectively decrease glucose-induced oxidative 
stress.  These studies also provide proof-of-principle that pharmacological induction of 
molecular chaperones may ameliorate DPN by helping sensory neurons to decrease 
oxidative stress and improve mitochondrial bioenergetics in response to glucotoxicity.    
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Chapter 1: Introduction 
1.1 Overview of Diabetes Mellitus 
Diabetes mellitus is a heterogeneous group of chronic metabolic disorders 
characterized by hyperglycemia and insulin deficiency or insulin resistance
1
.  Even as a 
non-communicable disease, the incidence of diabetes is rising at an epidemic rate due to 
pronounced changes in human environment, behavior, and lifestyle
2
.  Statistics from the 
International Diabetes Federation (IDF) projects that 9.9% or one adult in 10 of the 
global population will be diabetic by 2030
3
.  India, China, and the United States (U.S.) 
are currently the countries with the largest diabetic populations
3
.  As of 2010, roughly 
8.3% of the U.S. population was diagnosed with diabetes
4
.  Thus, diabetes and its 
association with an increased rate of premature morbidity and mortality has become a 
major challenge for public health in the 21
st
 century
3
.   
The National Diabetes Data Group (NDDG) and the World Health Organization 
(WHO) categorized diabetes mellitus into three major groups: Type 1 diabetes mellitus 
(T1DM), Type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM)
1,5
.  
All forms of diabetes can be diagnosed by the presence of classic diabetic symptoms 
along with the gross and unequivocal elevation of blood glucose with repeated testing
6-7
.   
Types of diabetes mellitus, risk factors and prevalence  
Type 1 diabetes mellitus (T1DM), formerly known as insulin-dependent diabetes 
is the consequence of chronic autoimmune disorder which selectively eliminates 
pancreatic β-cells, producing insulinopenia.  The absolute deficiency in insulin leads to 
 
 
2 
extreme hyperglycemia and classical diabetic symptoms such as polyuria, polydipsia 
(increased thirst), polyphagia (increased hunger), fatigue, and rapid weight loss
3
.  T1DM 
accounts for approximately 10% of all diabetic cases in North America and Europe
6
.  
Even though the onset of T1DM can occur in any age group, more than 80% of T1DM 
occurs in children and young adults with no prior family history of the disease
6
.  Current 
management of T1DM emphasizes glycemic control with mandatory insulin 
administration to maintain a patient’s life and prevent acute complications that can be 
fatal with negligence
3,8-9
.   
The clinical manifestation of T1DM is preceded by an asymptomatic period of 
highly variable duration.  During this period, four classic disease-associated 
autoantibodies can be detected as the first sign of emerging β-cell autoimmunity.  These 
include islet cell antibodies, insulin autoantibodies (IAAs), autoantibodies to the 65-kDa 
isoform of GAD and the tyrosine phosphatase-related IA-2 molecule
9
.  Both genetic 
predisposition and environmental factors have been proposed as triggers and potentiators 
of pancreatic β-cell destruction
8-9
.  The most important genes contributing to disease 
susceptibility are located in the HLA region of chromosome 6 where it also controls 
immune responses
6,9
.  Yet, less than 10% of individuals with genetically predisposed 
susceptibility progress to clinical disease
9
.  Early introduction of supplementary milk 
feeding during infancy, appearance of autoantibodies subsequent to enterovirus infections 
or increased immune response to foreign antigens have been proposed as environmental 
events that leads to HLA-mediated T1DM
9
.  Nevertheless, further studies are needed to 
provide concrete evidence to the cause(s) of T1DM and approaches to disease prevention.   
 
 
3 
Type 2 diabetes mellitus (T2DM), accounts for over 90% of the total diagnosed 
cases in diabetes and is the leading cause of the diabetes epidemic
1-3
.  T2DM is a 
heterogeneous metabolic disorder that precipitates from an array of factors but is 
characterized by insulin resistance and relative insulin deficiency
3
.  The prevalence of 
this disorder increases with age and obesity, with incident rates peaking  at 40-59 years of 
age
4,10
.  Patients with T2DM are often asymptomatic and can remain undiagnosed for 
decades.  About 50% of the T2DM patients are diagnosed during routine exams, diabetes 
screening, or while being treated for another condition
3,8,10
.  Thus, the total prevalence of 
T2DM is estimated to be twice the number of diagnosed cases
3,6
.  Chronic secondary 
complications include both macrovascular diseases and microvascular abnormality of the 
eyes, kidneys and peripheral nerves
1,3,5,10
.  Initial management of T2DM includes self-
monitoring and lifestyle changes
3,5
.  When patients fail to keep their glycemic level at 
bay, medications such as metformin and/or insulin are introduced
4
.   
Unlike T1DM, which is an autoimmune disease, the etiology of T2DM is 
polygenic.  The clinical course of T2DM progresses as muscles, liver and fat tissues fail 
to respond adequately to normal levels of insulin.  The ensuing, hyperglycemia initiates a 
continuous overstimulation of insulin secretion and produces hyperinsulinemia coincident 
with insulin resistance
10-11
.  Insulin deficiency eventually follows with deteriorated β-cell 
function as a result of the hyperglycemia
11
.  Strong genetic predispositions are often 
associated with T2DM
10
.  Multiple genes that control β-cell development or function 
have been associated with an increased risk of developing T2DM
12
.  Conditions such as 
obesity, hypertension and/or dyslipidemia are also considered as independent risk factors 
contributing to the pathogenesis of T2DM
10
.   
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Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance 
diagnosed during pregnancy and occurs in 2%-10% of all pregnancies
4,13
.  Most cases of 
GDM resolve with delivery, but infants born to mothers with GDM are often at risk of 
delivery complications due to macrosomia,  low blood sugar and jaundice
4-5
.  In addition, 
about 5%-10% of women with GDM are diagnosed with T2DM immediately or within 5 
years after pregnancy.  GDM resembles T2DM as they share many of the same risk 
factors and genetic susceptibilities
13
.  A combination of relatively inadequate insulin 
secretion and responsiveness are involved in both T2DM and GDM
1,4
.  Hence, these two 
diseases are considered as etiologically indistinct with one preceding the other
13
.  Even 
with recovery, women with GDM are more susceptible to the onset T2DM in the future
4-
5,10
.  
A number of other types of diabetes also exist and include conditions developed 
from specific genetic mutations, surgery, medications, infections, pancreatic disease and 
other illnesses
4
.  One can also be diagnosed as pre-diabetic when the blood glucose levels 
are intermediate between normal (99 mg/dl) and diabetic (126 mg/dl), impaired glucose 
tolerance (IGT)
4
.  Individuals with IGT have an increased risk of heart disease, stroke and 
T2DM
10
.  With change of lifestyle and adequate control of blood glucose, individuals 
with IGT can delay or prevent the onset of T2DM
3,5
.   
Diagnosis & Screening Criteria for Diabetes 
The WHO, the IDF and the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK), recommend fasting plasma glucose (FPG) tests, oral glucose 
tolerances tests (OGTT) or glycated hemoglobin (HbA1C) tests as diagnostic criteria for 
diabetes (Table 1)
5,7
.  The FPG test is the preferred method for diagnosing diabetes 
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because of its convenience and low cost
5,7
.  Blood glucose is measured in a patient who 
has fasted for at least 8 hours
5
.  The OGTT is a more sensitive method for diagnosing 
those with ambiguous FPG and individuals with IGT but without apparent symptoms
5-6
.  
After an 8 hr fast, plasma glucose level is measured immediately before and 2 hours after 
a 75-gram oral glucose challenge
5
.  Despite the accuracy of FPG or the OGTT test in 
diagnosing diabetes, single measures of glucose concentration are  incapable of 
predicting the prevalence of diabetes-specific complications
14
.  Thus, the level of HbA1C 
is recommended as a long-term measure of glycemic control. 
 
Diagnosis 
FPG Test 
Plasma Glucose 
Result (mg/dL) 
OGTT 
2-hour Plasma Glucose 
Result (mg/dL) 
HbA1c % 
Normal ≤ 99 ≤ 139 ≤ 6.0 
Prediabetes 
(Impaired glucose 
tolerance) 
100 – 125 140 – 199 6.0 – 6.4 
Diabetes* ≥ 126 ≥ 200 ≥ 6.5 
 
Table 1.  Diagnostic Criteria for Diabetes.  * Confirmed by repeating the test on a 
different day. 
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Glycated hemoglobin (hemoglobin A1c, HbA1C) is the product of non-enzymatic 
glycation when exposed to plasma glucose
14
.  HbA1C serves as an accurate and precise 
measure of blood glucose levels that are associated with an increased  risk for developing 
diabetic complications
14
.  Hence, an International Expert Committee that includes 
representatives of the American Diabetes Association (ADA), IDF, and the European 
Association for the Study of Diabetes (EASD) recommended HbA1c be used as part of 
the diagnosis for diabetes
14
.  Several advantages of the HbA1C assay surpass the FPG test, 
including greater convenience as fasting is not required, greater pre-analytical stability, 
and less day-to-day perturbations during periods of stress and illness
10
.  However, in 
some parts of the world the cost of HbA1C assay may preclude its availability
10
.  
Mortality & Economic Impact of Diabetes 
Diabetes substantially cripples society and its citizens via a direct burden to 
national healthcare systems and an indirect loss of productivity from diabetes-related 
morbidity and premature mortality.  According to IDF, the estimated healthcare 
expenditures due to diabetes, in 2011, account for $465 billion or 11% of the total 
healthcare expenditures in the world
3
.  Approximately 20% of the health care in the U.S. 
is spent by individuals diagnosed with diabetes
15
.  Although diabetes-induced death is 
likely under reported or under estimated, diabetes has been recognized as being 
responsible for a large portion of premature deaths in most countries
3
.  Diabetes was the 
7
th
 leading cause of death in the U.S. in 2007, individuals with diabetes along with 
secondary complications are twice as likely to die prematurely than their counterparts
3-4
.   
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1.2 Complications of Diabetes 
Without proper glycemic management, both acute and chronic complications may 
arise, leading to life-threatening events.  Patients with T1DM are vulnerable to both acute 
and chronic complications whereas individuals diagnosed with T2DM suffer more often 
from chronic complications. 
Acute Metabolic Complications  
Acute metabolic complications of diabetes consist of diabetic ketoacidosis 
(DKA), hyperosmolar non-ketotic coma (HNC), and hypoglycemia.  Both DKA and 
HNC are related to insulin deficiency and require hospitalization for treatments
16
.  
Hypoglycemia is a consequence of improper diabetes treatments with either oral agents 
or insulin therapy and can usually be treated in an ambulatory care setting
16
.   
DKA is clinically defined by an absolute insulin deficiency with hyperglycemia 
(>200 mg/dL) that leads to increased lipolysis, hyperketonemia (beta hydroxybutyrate 
>0.5 mmol/L) and acidosis (pH ≤7.3)
16
.  It is diagnosed predominately in T1DM patients 
as an initial manifestation of previously undiagnosed diabetes; under certain 
circumstances those with advanced T2DM may also experience DKA
16
.  Precipitating 
factors for DKA in known diabetic patients include infection, illnesses or poor 
compliance with insulin therapy
16
.  DKA is life-threatening and always requires 
professional medical attention.  The most important aspects in preventing DKA remain 
self-compliance and monitoring in diagnosed diabetic patients
16
.  
HNC is a type of diabetic coma associated with high mortality mostly in older 
T2DM patients
16
.  HNC precipitates from relative insulin deficiency and extreme 
hyperglycemia (>600 mg/dL) associated with elevated serum osmolality (>320 
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mosm/kg), polyuria and dehydration
16
.  HNC is distinct from DKA with the absence of 
lipolysis and ketoacidosis formation.  Patients will progress into stupor and coma if the 
condition is uncorrected.  Precipitating factors of HNC include infection, myocardial 
infarction, stroke or another acute illness and is almost always a sign of poor 
management from patients.  Hydration and small dose of insulin can be used to correct 
hyperglycemia
16
.   
Chronic Complications of Diabetes 
Chronic diabetic complications are the major source of morbidity and mortality in 
diabetic patients.  Despite the differences in pathogenesis, both T1DM and T2DM 
patients are vulnerable to chronic complications
17
.  Chronic hyperglycemia together with 
other risk factors induce physiological changes and abnormalities that are categorized as 
macrovascular and microvascular diseases
17
.  Landmark studies from the Diabetic 
Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes 
Study (UKPDS), showed that intensive control of blood glucose may attenuate, delay or 
prevent the progression of diabetic complications, but reversal of the complications does 
not occur
18-19
.   
Vascular Diseases 
The rapidly escalating population of patients with T2DM contributes to the 
growing epidemic of macrovascular complications that includes diseases of coronary 
arteries, peripheral arteries, carotid vessels and ischemic stroke
20
.  Diabetes mellitus has 
been considered as an independent risk factor and predictor for the development of 
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arterial dysfunctions, which accounts for over 50% of all morbidity and mortality in 
diabetes
5,17
.  
The vast majority of diabetic patients with vascular disease died of causes related 
to atherosclerosis
21
.  It is the product of chronic hyperglycemia, dyslipidemia and insulin 
resistance
20
.  Biochemical studies support that chronic hyperglycemia can contribute to 
atherogenesis and endothelium dysfunction through the induction of oxidative stress and 
inflammation
20-21
.  Thus, aggressive glycemic control and management of abnormal 
metabolic states are required to achieve primary or secondary prevention of the disease.  
Indeed, multiple clinical observations have demonstrated a linear correlation between 
intensive glycemic control and decreased risk and progression of macrovascular events in 
T1DM and T2DM patients
18-19,22-25
.   
Retinopathy 
Retinopathy is a common microvascular complication of diabetes.  Almost all 
patients with T1DM and over 60% of patients with T2DM will suffer from some degree 
of retinopathy within twenty years after of diagnosis
26
.  The damage in retinopathy 
originates from microvascular leakage and occlusion of the retinal capillaries
26
.  The 
duration and severity of hyperglycemia is the major factor dictating the morbidity of 
diabetic retinopathy
18-19,22
.  Hyperglycemia is thought to modulate disease progression 
through several biochemical processes including polyol accumulation, formation of 
advanced glycation end products (AGEs), oxidative stress and activation of protein 
kinase C (PKC)
27
.  Severe vision loss or even blindness as a consequence of diabetic 
retinopathy can be prevented in patients with proper glycemic control and with treatments 
such as photocoagulation and vitrectomy
26
.   
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Nephropathy 
Diabetic nephropathy is the leading cause of renal failure and kidney transplant in 
North America and Europe
28
.  It affects around 40% of all the diabetic patients with 
progression toward albuminuria followed by persistently elevated plasma creatinine that 
eventually leads to death
28
.  The cumulative incidence of albuminuria (urine albumin > 
300 mg/day) has also been considered as a powerful independent predictor of 
cardiovascular morbidity and mortality in T2DM diabetic patients
29
.  Like retinopathy, 
the main potentiator of this disease in susceptible individuals is chronic hyperglycemia
30
.  
Other putative risk factors include hypertension, dyslipidemia and glomerular 
hyperfiltration
30
.  Thus, intensive blood glucose control remains as the main method for 
preventing the onset of nephropathy
30
.   
Neuropathy 
Diabetic neuropathy refers to the degeneration of the peripheral nerves which 
affects 60%-70% individuals within twenty years of diabetes and gives rise to significant 
morbidity and mortality
31
.  Unfortunately, the true prevalence of this complication is 
unknown as epidemiologic studies of diabetic neuropathy are limited to clinically 
diagnosed individuals that receive continuous medical care
32
.  Diagnosing diabetic 
neuropathy is performed by clinical examinations that quantitatively measure 
electrophysiologic, sensory and autonomic function
33
.   
Diabetic neuropathy is a heterogeneous group of nerve disorders.  The type of 
nerve fibers and unique pathophysiologic and prognostic features of various neuropathy 
syndromes are summarized in Figure 1-1
34
.  Sensory and autonomic neuropathy generally 
progress gradually with the increasing duration of diabetes and are often asymptomatic
34
.  
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Mononeuropathies, radiculopathies or acute painful neuropathies, however, usually 
present with severe symptoms but remit completely
34
.   
 
Figure 1-1 Different clinical presentation of diabetic neuropathy
34
.  
Among all diabetic peripheral neuropathies, distal peripheral polyneuropathy 
(DPN) is the most common chronic syndrome.  DPN may be asymptomatic in over 50% 
of patients and is responsible for >80% of amputations following foot ulceration or 
injury
33
.  Progression of DPN is closely related to the duration and severity of 
hyperglycemia in both T1DM and T2DM patients
18-19
.  Multiple etiologies including 
metabolic abnormalities, oxidative stress and neurohormonal growth-factor deficiency 
have been proposed to contribute to the development of DPN
34
.   
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1.3 Distal Peripheral Polyneuropathy  
One of the most frequent and troublesome complications of diabetes mellitus is 
distal peripheral polyneuropathy (DPN).  It accounts for over 50% of all diabetic-relate 
peripheral neuropathies and give rise to incapacitating pain, sensory loss, foot ulceration, 
infection, gangrene and poor wound healing
35
.  In many cases, the end result is lower 
limb amputation.  Progression of this complication along with autonomic neuropathy is a 
major cause in mortality for diabetic subjects.   
Signs & Symptoms  
The most common early abnormality indicative of DPN is asymptomatic nerve 
dysfunction as reflected by decreased nerve conduction velocity (NCV) and amplitude of 
compound action potentials (APs) in peripheral sensory and motor nerves
33
.  These 
changes are usually followed by a loss of vibratory sensation and ankle reflexes
36
.  
Clinical indicators of DPN can be divided into negative and positive symptoms
33-34
.  The 
former consist of loss of sensory perception to pain, pressure or temperature; muscle 
weakness may occur as a sign of motor nerve dysfunction
33
.  Positive symptoms include 
burning, paresthesias, allodynia and hyperalgesia in feet and lower limbs, which are 
typically worse at night, may be the result of neural hyperexcitability
35
.  These symptoms 
usually begin from the distal end of the hands and feet with proximal progression, 
reflecting the dying-back nature of DPN.   
Pathophysiological Features 
The classical manifestations of DPN progress bilaterally in a “glove-and-
stocking” distribution beginning from the most distal extremities of the hands and feet
32
.  
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The mixed symptoms and sensory loss are evidence that both large and small afferent 
nerve fibers are affected
32
.  Structural changes of the peripheral nerves during disease 
progression include axonal atrophy and degeneration, paranodal demyelination, failure of 
re-innervation, and abnormal microvascular changes
35
.  Clinical and animal studies have 
shown that the progressive nerve degeneration and compromised regenerative plasticity 
are closely related to the degree of hyperglycemia and the duration of diabetes
37-39
.  Skin 
biopsies from diabetic patients showed significant epidermal denervation, a sign of distal 
sensory epidermal axon loss and were accompanied by functional impairments
40
.  Loss of 
axonal caliber associated with axonal shrinkage indicates a combined insult on axons and 
Schwann cells (SCs) as has been reported in teased nerve-fiber studies and diabetic 
animal models
41-43
.  Attempted skin re-innervation and sural nerve regeneration were 
badly compromised with increased diabetic duration
40,44-45
.  In advanced diabetes, 
evidence for axonal, glial and vascular injuries is detectable in most cases of DPN
46-47
.   
While the discussions above provide some insights on the morphological changes 
of peripheral nerves, multiple questions related to the etiology of DPN remain unclear.  
Additionally, the different clinical presentations of the disease and its symptoms in 
diabetic patients have made predicting disease progression a challenge.  Up-to-date, 
treatments against DPN remain symptomatic and are limited.   
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1.4 Current Therapeutic Management & Strategies 
Once neuropathy is diagnosed, therapy can be instituted with the goal of reducing 
symptoms and delaying disease progression.  Current available therapies may be 
classified as symptom management, primary prevention, and causal treatment based on 
etiology.   
Symptomatic Managements 
Pain is a severe consequence affecting patients’ quality of life and yet remains 
one of the most difficult issues to manage in DPN.  Nevertheless, newly diagnosed 
patients are often unaware of pain as a symptom of DPN and fail to report it.  The 
prevalence of painful diabetic neuropathy increases with age and duration of diabetes.  
Hence, symptomatic therapies are often aimed at reducing pain. 
The commonly prescribed treatments for painful DPN are antidepressants (TCAs 
and SSRIs) where combinatorial drug therapies have demonstrated the best efficacy in 
reducing pain and paresthesias in over 80% of patients
48-49
.  However, antidepressants 
such as TCAs always carry a risk for developing adverse drug reactions in individuals.  
The nature and chronicity of neuropathic pain also promotes the use of anticonvulsants 
(carbamazepine and gabapentin) and opioid analgesics (tramadol and NSAIDs)
34
.  
Nevertheless, these drugs carry a risk of high-dose tolerance, physical dependence and 
provide only marginal to moderate relief of pain
32
.  Topical analgesics such as capsaicin 
have been reported to exacerbate pain with temporary burning sensation in the initial 
stage of the treatment but lead to pain relief by decreasing substance P levels in small 
sensory fibers
32
.  Mexiletine is a type of antiarrhythmic medication that is prescribed only 
as an alternative agent in patients under extreme, refractory symptoms with no cardiac 
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risk
48
.  Clearly, therapies aimed at reducing painful stimuli in neuropathy are 
polypharmacy nightmares fraught with adverse effects and only moderately efficacious. 
Hence, more-efficacious and neuropathy-specific medications are needed.  
Intensive Glycemic Control 
Comprehensive clinical studies have suggested an intimate correlation between 
hyperglycemia and the severity of DPN.  The Rochester Diabetes Project was the first 
community-based study of neuropathy in a U.S. population
31
.  Patients diagnosed with 
T2DM were followed over 25 years and showed an increase in prevalence of clinically 
detectable DPN from 4% for diabetes of short duration (<5 years) to 15% after 20 years 
of diabetes
31
.  The follow-up study from the Rochester Diabetic Neuropathy Study 
(RDNS) showed that DPN was of greatest prevalence among all forms of neuropathy 
diagnosed in both Type 1 and Type 2 diabetic patients
50
.   
The Diabetic Control and Complications Trial (DCCT) study reported a 
statistically significant effect of intensive insulin therapy on reducing cumulative 
incidence of diabetic neuropathy
18
.  The prevalence rates for clinically diagnosed 
neuropathy in the T1DM were reduced by 60% in those treated by intensive insulin 
therapy at 5 years compared with conventional treatment, which involved less intensive 
glycemic control
18
.  The United Kingdom Prospective Diabetes Study (UKPDS), which 
followed a cohort of more than 3,000 patients with T2DM for over 15 years, also showed 
similar correlation of glycemic control and the reduction in the incidence of 
neuropathy
19,22-23,28
.  Particularly, patients who received intensive glycemic therapy 
(insulin or sulfonylurea) was associated with improvement in vibration perception 
compared with those assigned to conventional regimen
19
.  The difference between the 
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two treatment groups was even greater when all microvascular complications were 
considered.  These findings underscore the importance of early, intensive glycemic 
control in the prevention of diabetic-related complications including neuropathy and 
point to systemic hyperglycemia as the universal trigger responsible for the onset of 
diabetic complications.  However, despite these favorable results, DPN could not be 
completely prevented in the above studies, suggesting that additional etiological factors 
may significantly contribute to disease progression.   
Pathogenic Mechanism Specific Management  
Several classes of compounds have been developed to counteract specific 
pathogenic mechanisms involved in DPN.  Most of the drugs have demonstrated 
promising results in preclinical animal prevention studies, but have delivered 
disappointing results from clinical trials.  Some etiological treatment paradigms include: 
inhibitors of the polyol pathway and advanced glycosylation products, anti-oxidant, drugs 
that normalize prostanoid metabolism and recombinant human nerve growth factor.    
Aldose reductase inhibitors (ARIs) held promise for the treatment and 
management of DPN.  It is argued that since hyperglycemia increases glucose flux 
through the polyol pathway, inhibition of the pathway using ARIs could prevent tissue 
accumulation of sorbitol and reduce changes in redox potential.  In clinical evaluations of 
the ARI, Tolerestat, diabetic patients with symmetrical polyneuropathy showed 
improvement in autonomic function tests and vibration perception with daily 
administration of the drug whereas placebo-treated patients showed deterioration in most 
of the variables measured
51-52
.  Similarly, a 12-month study with the ARI Zenarestat, 
showed a dose-dependent improvement in nerve fiber density accompanied by an 
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increase in NCV
53
.  This same response has been noted in experimental ARI trials in 
diabetic rats
54
.  Unfortunately, follow up studies have shown that regenerating nerve 
fibers following ARI treatment never reach functional or structural maturity
36
.  Overall, 
inhibition of aldose reductase may be efficacious as a preventative measure during the 
early metabolic phase of DPN, but insufficient to reverse established neuronal deficits.    
Another pathogenic-derived drug target is to inhibit the formation of advanced 
glycation end-products and free radicals with aminoguanidine.  Animal studies using 
aminoguanidine showed improvements in nerve blood flow, vascular permeability, NCV 
and structural parameters
55-57
.  Controlled clinical trials in humans, however, have been 
abolished due to toxicity
34
.  However, inhibiting the effects of advanced glycosylation 
products by blocking their interaction with the receptor for AGEs (RAGE) may hold 
promise
58-59
.  
Linoleic acid is an essential fatty acid constituent of neuronal membranes and is a 
substrate in prostanoid metabolism.  The metabolism of linoleic acid is impaired in 
diabetes and placebo controlled clinical trials employing γ-linoleic acid (GLA) have 
reported improvement in clinical measures and electrophysiologic testing
60-61
.  Some 
prostaglandin trials have also reported positive treatment effects following short-term 
intravenous administration of lipo-PGE
36
.  Little adverse effects were noted following 
administration of these drugs.  
Alpha-lipoic acid (ALA) is a thiol replenishing and redox modulating agent.  
Experimental data has shown that ALA is a potent lipophilic free radical scavenger that is 
capable of stimulating glucose uptake and pyruvate-dehydrogenase activity, thereby, 
reducing the level of lactate and pyruvate in serum
62-64
.  Short-term studies with 
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intravenous infusion of ALA have demonstrated increased insulin sensitivity and 
improvement in clinical symptoms in diabetic patients
65-66
.  Nevertheless, long-term 
followed up studies did not show further improvement of the clinical symptoms or 
neurological deficits despite the slightly enhanced electrophysiology
67-68
.   
Impaired neurotrophic support has been associated with peripheral deficits in 
experimental diabetic models
34
.  Treatment with  recombinant human nerve growth factor 
(rhNGF), a selective trophic factor for small-fiber sensory and sympathetic ganglion 
neurons, has restored neuropeptide levels and prevented sensory neuropathy in diabetic 
animals
69
.  Although early clinical trials of rhNGF appeared to show some beneficial 
effects on sensory nerve function, regrettably, the improvement was less than significant.  
In addition, there was challenge in the route of administration as direct injection of 
neurotrophic factors is associated with hyperalgesia and pressure allodynia at the site of 
entry
70-71
.  
In summary, numerous clinical trials have been undertaken to test potential 
etiology-targeted treatments and with few exceptions, most have been disappointing.  
This disappointment may be accounted for by the fact that the biochemical progression of 
DPN in individual patients is never uniform.  Thus, the therapeutic approach to DPN has 
to be reconsidered.  It appears that this multi-factorial disease is best treated with multi-
drug interventions in order to prevent, block and/or reverse several pathogenic pathways 
simultaneously.  Such approaches however require in-depth knowledge of the natural 
history of the disease, which is reviewed in the following sections. 
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1.5 Pathogenesis of Distal Peripheral Neuropathy 
Clinical studies and experimental observations of DPN give rise to two plausible 
etiologies contributing to its pathogenesis that may be operating simultaneously or in 
parallel.  The dying-back of the longest axons may manifest with impairments in growth 
factor synthesis and axonal transport
45
.  Impaired protein synthesis or transport, including 
vital neurotrophic support may be the source of axonal atrophy and compromise nerve 
regeneration in DPN
72
.  Alternatively, chronic hyperglycemia and inflammatory 
responses may provoke the accumulation of local injuries and insults that lead to nerve 
dysfunction
35
.  Regardless of whether DPN initiates with distal axons dying back, 
multiple proximal injuries or both, in most cases, sensory axon degeneration prevails.  
Sensory neuron loss with replacement by satellite cells (nests of Nageotte), vacuolation 
of sensory neurons and apoptosis have been reported in both clinical patients and animal 
studies
38,73
.  Hence, studying the molecular changes in sensory neurons, glia and 
peripheral nerves will provide us with better understanding of the disease.   
Regulation of Glucose Transport in Peripheral Nervous System 
The majority of the metabolic energy in peripheral nerves is consumed through 
axolemma repolarization
74
.  However, blood-nerve and perineurial diffusion barriers limit 
the access of free fatty acids as substrates for energy production in peripheral axons and 
energy from oxidation of ketones plays only a minor role
74-75
.  Thus, glucose oxidation 
becomes the major source of metabolic energy for the peripheral nerves and neurons
74
.  
Large amounts of glucose are taken up via endoneurial capillaries across the blood-nerve 
barrier or through the plasma membrane and cytoplasm of myelinated SCs wrapping 
around the axons
76
.  Peripheral nerves require a constant metabolic energy supply but are  
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not able to uptake glucose in an insulin-dependent manner
77
.  Therefore, despite the 
presence of insulin receptors in dorsal root ganglia (DRG) and peripheral nerve, glucose 
uptake and utilization in neurons and glial cells depends solely on the extracellular 
concentration of glucose
75
.   
Cellular glucose uptake is achieved via plasma membrane carrier proteins that 
transfer glucose across the lipid bilayer
78
.  SCs express two isoforms of insulin 
insensitive glucose carriers, GLUT1 and GLUT3, which passively transport glucose into 
peripheral nerves through facilitative diffusion
76,78
.  Expression of GLUT1 is 
predominantly in SCs at the node of Ranvier, whereas GLUT3 is preferentially expressed 
in the paranodal regions of SC and nodal axons
76,79
.  Under conditions operative in vivo, 
SCs that are not part of blood-nerve barrier express low levels of GLUT1 and at steady 
state, take up a higher proportion of glucose than neurons
76
.  Axonal modulation can 
increase the expression of GLUT1 in SCs, thus affecting glucose uptake and utilization
74
.  
The delivery of glucose from SCs to the axons and neurons is modulated by axonal-glial 
interactions which also regulate SC proliferation, differentiation and receptor 
expressions.  Hence, the state of chronic hyperglycemia during diabetes can render 
peripheral nerves more vulnerable to glucotoxicity due to increased glucose uptake into 
SCs and neurons.  
The Role of Schwann Cells in Diabetic Neuropathy 
Schwann cells (SCs) are the principle glial cells in the peripheral nervous system.  
They are part of the perinurial blood-nerve-barrier and are responsible for proper 
saltatory conduction along axons, provide trophic support for neurons, and are essential 
for nerve development and regeneration
80
.  Morphological and functional studies indicate 
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that SCs undergo substantial damage in diabetes and related animal models
73,81-83
.  
Biochemically, hyperglycemia may induce metabolic damage through the polyol pathway 
as aldose reductase (AR) is primarily localized to SCs in peripheral nerve.  
Overexpression of AR through a SC-specific promoter exacerbates NCV deficit in 
diabetic transgenic mice and implicates the polyol pathway in dysregulation of SCs in 
diabetes
84
.   
Additionally, there is evidence indicating that impaired neurotrophic support in 
glia contributes to neuronal dysfunction in diabetes
36,85
.  Hyperglycemia depleted nerve 
growth factor (NGF) production in cultured SC cells and treating SCs with aldose 
reductase inhibitors (ARIs), increased NGF secretion/synthesis and prevented 
hyperglycemia-induced apoptosis
73,86-87
.  The loss of trophic support and dysregulation of 
axonal-glial interaction can also severely compromise myelination and axonal 
regeneration.  A study by Eckersley and co-workers showed that ErbB2, a critical axon-
SC signal receptor, was decreased in SCs isolated from diabetic rats whereas expression 
of p75NTR, which is capable of inducing autocrine apoptosis in SCs, was enhanced
88
.  
As a result, fewer SCs become available to support nerve regeneration.  
Glucose Neurotoxicity 
Various neuropathic syndromes seen in patients with diabetes may be the result of 
multiple etiologies.  Nevertheless, the common symptom in diabetes is systemic 
hyperglycemia and the DCCT has shown that elevated blood glucose clearly plays a 
central role in the development and progression of diabetic neuropathy
18
.  Chronic 
hyperglycemia increases intracellular glucose metabolism and leads to neuronal and glial 
cell damage that is often referred to as glucotoxicity
77
.  Studies of impaired peripheral 
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nerve function in DPN hypothesize that the insult from hyperglycemia is likely to be 
metabolic, vascular or both
89
.  Chronic hyperglycemia can increase metabolic insults 
through activation of alternative glucose metabolic pathways such as the polyol and 
hexosamine pathways.  Under normal conditions, these pathways utilize only a small 
percent of total glucose but serve as conduits for the shunting of excess glucose under 
diabetic conditions.  However, the enhanced activity of these pathways alone cannot 
account for the extensive nerve damage that occurs in DPN and the following sections 
will highlight some of the major pathways that are thought to contribute to DPN.   
Polyol (Sorbitol) Pathway 
The polyol (sorbitol) pathway converts glucose to fructose via a two-step 
reduction/oxidation.  The rate-limiting step converts glucose to sorbitol by aldose 
reductase (AR) followed by the formation of fructose through oxidation of sorbitol.  
Under normoglycemic conditions, glucose is converted to glucose-6-phosphate by 
hexokinase which has a higher affinity for glucose than AR.  Hence, only trace amounts 
of sorbitol are formed
90
.  However, hyperglycemia increases ambient glucose uptake in 
the peripheral nerve, saturates hexokinase, and shunts the excess glucose to the polyol 
pathway, leading to intracellular sorbitol accumulation, depletion of organic osmolytes, 
reducing agents and antioxidants
90
.   
Polyol pathway activation was the first cogent hypothesis in the search to link 
altered glucose metabolism with nerve dysfunction
91-92
.  In early tissue damage, 
intracellular sorbitol accumulation induces hyperosmotic swelling.  This leads to the 
compensatory efflux of other organic osmolytes such as taurine and myo-inositol (MI)
90,93
.  
Nevertheless, osmotic pressure from sorbitol accumulation is considered to play a minor 
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role in tissue damage in neuropathy
92
.  Instead, the major mechanism leading to various 
metabolic disturbances due to increased activity of the polyol pathway are thought to 
arise from an increased production of ROS and depletion of antioxidants/reducing 
agents
77,93
.  Taurine is an endogenous antioxidant that counteracts oxidative stress and 
NGF deficit by attenuating nerve blood flow and nerve conduction in diabetic nerves
94
.  
Thus, taurine depletion compromises antioxidant defense mechanisms and promotes 
nerve degeneration
94
.  Increased activity of AR also disrupts redox balance and increases 
oxidative stress in the peripheral nerve under diabetic conditions
90
.  AR utilizes NADPH 
as substrate for the reduction of glucose to sorbitol and can alter the cellular ratio of 
NADPH/NADP. A decrease in NADPH levels can compromise the recycling of 
glutathione since NAPDH is a co-factor for glutathione reductase, and reduce the 
clearance of H2O2 from mitochondria
95
.  Additionally, depletion of NADPH also 
suppresses nitric oxide production, thereby eliciting microvascular derangements and the 
slowing of nerve conduction
96-97
.  Metabolic damage via the polyol pathway may be 
highly localized in peripheral nerves since  AR is localized primarily in the paranodal 
cytoplasm of SCs as well as in endoneurial capillaries
98
.   
Hexosamine Pathway 
During normoglycemia, small amounts of the glycolytic intermediate, fructose-6 
phosphate are shunted from glycolysis to the hexosamine pathway, which drives the 
formation of uridine diphosphate-N-acetyl glucosamine (UDP-GlcNAc).  As diabetes 
increases the flux of glucose through glycolysis, the volume of metabolic intermediates 
increases and can be shunted into the hexosamine pathway.  UDP-GlcNAc formation can 
affect protein function by attaching O-GlcNAC to the serine and threonine residues of 
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numerous proteins and transcription factors.  Studies of O-GlcNAC biology suggest that 
the hexosamine pathway functions as a cellular “sensor” for energy availability and plays 
a role in insulin resistance and macrovascular complications
93
.  
Several gene products including leptin are altered under the hyperglycemia-driven 
activation of hexosamine pathway.  Sp1 is a transcription factor that regulates the 
expression of tissue type plasminogen activator inhibitor-1 (PAI-1) and transforming 
growth factor-β1 (TGF-β1) and is modified by UDP-GlcNAc in diabetic complications.  
Dysregulation of these genes increases nerve ischemia and oxidative stress, which may  
help contribute to the symptoms of DPN
93
.  However, a direct role for the hexosamine 
pathway in the development of DPN has not been described. 
Protein Glycation 
Reducing sugars react spontaneously and non-enzymatically with amino groups in 
proteins forming a reversible Schiff base.  Rearrangements of the labile Schiff base 
product produces irreversible intermediates known as ketoamines or Amadori products
99
.  
Under normal physiological condition, glucose is in equilibrium with Amadori products 
and only a small portion of the intermediates undergo further oxidation yielding 
irreversible cross-linked products termed advanced glycation end products (AGEs)
100
.  
AGEs accumulate on long-lived proteins and hence the rate of AGE formation is directly 
proportional to the duration and concentration of glucose, the rate of protein turnover and 
the permeability of tissue to free glucose
99-100
.  Glycolytic intermediates and reactive α-
dicarbonyl compounds can glycate proteins at a much faster pace than glucose thus 
promoting intracellular formation of AGEs in diabetes
100-102
.  Some glycating agents 
include glyceraldehyde-3-phosphate, 3-deoxyglucosone (3-DG) and methylglyoxal 
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(MGO), which is the most reactive triose.  MGO can be produced from glyceraldehyde-
3-phosphate, fructose and oxidative decomposition of polyunsaturated fatty acids
99,101,103
.   
AGEs have been shown to alter enzymatic activity, decrease ligand binding, 
modify protein half-life and alter immunogenicity
99
.  Aggregates of AGE deposition were 
found in the cytoplasm of endothelial cells, pericytes, axoplasm and SCs of both 
myelinated and unmyelinated nerve fibers of human diabetic peripheral nerves
104
.  Ryle 
et al showed that peripheral nerve cytoskeletal proteins are vulnerable to AGE 
accumulation with increased duration of diabetes
105
.  Excess AGE deposition in diabetic 
nerves and skin correlate with a reduction in myelinated fiber density and the onset of 
clinical manifestations of DPN
104,106
.  Thus, enhanced AGEs play a role in the 
development of diabetic neuropathy.   
Some biological effects of AGEs are modulated through the interaction with their 
cellular receptors (RAGEs), which are expressed in smooth muscle cells, macrophages, 
endothelial cells, astrocytes and microglia
107
.  Dramatic increases in RAGE expression 
are found in peripheral epidermal axons, sural axons, SCs and DRG sensory neurons of 
diabetic mice along with progressive electrophysiological and structural abnormalities
108
.  
Interaction of AGE with RAGE increases oxidative stress and activates pro-inflammatory 
pathways through the transcription factor, NF-κB
100
.  Vincent et al showed that activation 
of RAGE promoted neuronal injury via the formation of ROS by NAD(P)H oxidase in 
DRG sensory neurons
109
.  Abolishing RAGE expression via genetic deletion attenuated 
the onset of DPN in diabetic RAGE knockout mice
108
.  Consequently, these studies 
suggest that RAGE may be a potent therapeutic target for treating diabetic complications. 
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1.6 Oxidative Stress & Mitochondria Dysfunction. 
Oxidative stress is a well-recognized mechanism in the pathogenesis of 
neurodegenerative diseases, and has been proposed as a central mechanism linking the 
aforementioned metabolic pathways with various biochemical abnormalities in diabetic 
neuropathy.   
Reactive Oxygen Species 
Although oxidative phosphorylation (OxPhos) is nearly always orchestrated with 
great rapidity and precision, reactive oxygen species (ROS) are occasionally generated as 
byproducts that readily react with a variety of cellular components
110
.  The best known 
ROS is the superoxide radical (O2·
-
).  Approximately 4% of electrons that enter the 
mitochondria respiratory chain lead to the formation of O2·
-111
.  Superoxide can also act 
as a precursor for other reactive species
112
.  The most potent oxygen species, hydroxyl 
radical is formed from O2·
-
-driven Fenton reaction with hydrogen peroxide (H2O2) in the 
presence of transition metals (e.g., copper and iron; Eqns 1 & 2)
113
.  Superoxide can also 
react directly with H2O2 (Eqn 3)
114
.   
O2·
-
 + Fe
3+  
      O2 + Fe
2+   
(1) 
H2O2 + Fe
2+   
     ˙OH + OH
-
 + Fe
3+
  (2) 
O2·
-
 + H2O2
  
      O2 + H2O + ˙OH
   
(3) 
Oxidative free radicals are removed from the cell by antioxidants.  The enzyme 
superoxide dismutase (SOD) is found in nearly all cells and is considered a first-line 
defense against ROS.  SOD catalyzes the conversion of O2·
-
 to H2O2.  Nonetheless, the 
uncharged H2O2 is a powerful oxidizing agent too and is capable of diffusing rapidly 
across the mitochondrial membrane into the cytosol where it can potentially react to yield 
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other ROS
112
.  H2O2 can be degraded to water and oxygen by enzymes such as catalase 
and glutathione peroxidase, which generates reduced glutathione (GSH).  
Most free radicals are extremely short-lived, but they readily extract electrons 
from other molecules, converting them to free radicals and thereby initiating a chain 
reaction
115
.  The random nature of free-radical attacks makes it difficult to characterize 
their reaction products, but all classes of biological molecules are susceptible to oxidative 
damage caused by ROS.  ROS production can induce tissue damage through DNA and 
protein modifications and lead to endothelial injury and tissue hypoxia due to loss of 
vasodilation
110
.  Because mitochondria are the major site of cellular oxidative metabolism, 
its lipids, DNA and proteins bear the brunt of ROS-related damage
116
.  Many 
neurodegenerative diseases including Parkinson’s, Alzheimer’s and Huntington’s 
diseases are associated with oxidative damage to mitochondria
117
.  Such observations 
have led to the “free radical theory” of aging, which holds that reaction of free-radicals 
arising from oxidative metabolism are at least partially responsible for the aging process
93
.   
Mitochondrial Damage through Oxidative Stress  
Although the contribution from individual sources may vary, mitochondrial 
oxidative phosphorylation (OxPhos) is the primary site of ROS production in most 
mammalian cells.  As discussed above, all cells including neurons have the capacity to 
neutralize ROS under normal conditions via antioxidants.  However, in diabetes, 
intracellular hyperglycemia increases mitochondrial activity leading to a surplus 
production of ROS.  The buildup of ROS in neurons, coupled with the depletion of 
reducing equivalents as a result of activation of other metabolic and inflammatory 
pathways (Figure 1-2), eventually overwhelms the endogenous antioxidant reserves 
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leading to the damage of cellular proteins, DNA, membranes, organelles and neuronal 
function
116
.  Given the typical distal-to-proximal progression of DPN, DRG sensory and 
motor neurons are especially vulnerable to damage because of their long – up to 1 meter 
in length – mitochondria-rich axon that directly accesses the nerve blood supply
118
.  As a 
result, axonal mitochondria support a tremendous energy demand and become a primary 
source of ROS production 
119
.  Swollen mitochondria, disruption of internal cristae or, in 
some cases, shrinkage of organelles is observed in human diabetic nerve and skeletal 
muscle
120-122
.  Similar structural abnormalities in mitochondria have been described in 
SCs of galactose-fed rats and in DRG neurons of long-term STZ-diabetic animals
123-124
.  
Ultrastructural analysis of the neuromuscular junction of short-term STZ-diabetic mice 
showed ballooning mitochondrial structure in nerve endings with altered cristae 
formation
125
.  Collectively, these data suggest that an elevated rate of OxPhos increases 
oxidative stress and mitochondrial injury in DRG neurons and contributes to the 
pathogenesis of DPN. 
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Figure 1-2 Schematic of hyperglycemic effects on biochemical pathways in DPN.  A 
combination of hyperglycemic and oxidative stress activate the detrimental pathways such as 
AGE, polyol, hexosamine and PKC which lead to redox imbalance, gene expression disturbances, 
and further oxidative stress.  These pathways also induce inflammation and neuronal dysfunction, 
contributing to axonal degeneration and impaired nerve re-innervation.  Abbreviations: NF- κB 
nuclear factor kappa B, PKC protein kinase C, AGE advance glycation endproducts, ROS reactive 
oxygen species GSH glutathione, GSSG oxidized glutathione, UDPGlcNAc UDP-N-
acetylglucosamine.  (Modified from Figueroa-Romero et al. Rev Endocr Disord, 2008 9: 301-314) 
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Mitochondrial Dysfunction in Diabetic Neuropathy 
There is mounting evidence indicating that hyperglycemia-induced mitochondria 
dysfunction caused by defects in energy metabolism and oxidative damage in peripheral 
neurons contributes to the pathogenesis of DPN.  The modes of anatomical abnormalities 
and functional degeneration in DPN, however, have yet to be fully elucidated.  
As the primary site of ROS formation, mitochondrial DNA (mtDNA), proteins 
and membrane are susceptible to oxidative modifications which ultimately compromise 
mitochondria function.  Neuronal mtDNA is more prone to oxidative damage than that in 
glial cells
126
.  Though little is known about the role of oxidative damage to mtDNA in 
DPN, analysis of patients with dominant optic atrophy, an axonopathy that shares 
pathological features with DPN, showed decreased neuronal mtDNA content
127
.  
Reduced antioxidants as a result of oxidative stress have been shown to destabilize 
mtDNA and prevent cAMP responsive element-binding protein (CREB)-mediated 
transcription in mitochondria
128
.  As mtDNA encodes 13 essential protein subunits of the 
mitochondrial respiratory chain complexes, disruption of mtDNA will inevitably impair 
OxPhos activity, leading to energy failure.  In fact, depolarization of mitochondrial 
membrane potential (ΔΨm) and depletion of high-energy phosphorylated intermediates 
have been reported in diabetic animals, supporting the view that ATP production by the 
mitochondria in diabetes is sub-optimal
129-132
.  Several lines of evidence imply that the 
loss of ΔΨm may be associated with mitochondria-mediated apoptosis in DPN.  Studies in 
diabetic rats have demonstrated that elevated ΔΨm, along with decreased Bcl-2 levels and 
translocation of cytochrome c, increased apoptosis in both intact and acutely dissociated 
DRG neurons as early as 3 weeks after induction of diabetes
133
.  Although few cell bodies 
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undergo apoptotic death, both in vivo and in vitro models of diabetes have shown 
caspase-mediated apoptosis along with ROS production and mitochondria 
dysfunction
73,130,134-135
. However, apoptotic death of neurons is not considered to 
substantially contribute to the pathogenesis of DPN. 
Mitochondria have been reported to accumulate in demyelinated axonal segments 
and in regions of disrupted axo-glial junctions in pathologic states
118
.  It is possible that 
prior to cellular apoptosis, hyperglycemia induces a local apoptotic program via damaged 
mitochondria at the axonal level.  A shift in mitochondrial dynamics towards metabolic 
fission, yielding clumps of small, non-functional mitochondria may lead to the ‘dying 
back’ of axons with apoptotic feature
118
.  This is evident by an increase in dynamin 
related protein 1 (Drp1), which initiates metabolic fission at times of stress, at 
mitochondria in models of diabetic neuropathy
136-138
.   
In summary, the injury cascade through oxidative stress and mitochondrial 
dysfunction outlined above suggest that DPN precipitates from an interaction and 
intersection of multiple pathways and mechanisms.  Hence, potential therapeutic 
interventions may need to be directed at multiple pathogenic targets.  Alternatively, we 
have proposed that the management of DPN may benefit from upregulating a broadly 
cytoprotective response in peripheral nerve.  Induction of molecular chaperones promotes 
a pro-survival heat shock response that has been shown to be protective in 
neurodegenerative diseases and may also be applicable in the case of DPN.  
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1.7 Heat Shock Protein & Neurodegenerative Diseases 
Accumulation of misfolded proteins concomitant with a decrease in proteasomal 
activity and altered functional capacity of molecular chaperones are considered a result of 
normal aging
139
.  Nevertheless, many systemic and neurodegenerative diseases fall into a 
class of “protein-misfolding disorders”, or “protein-conformational disorders”
140
.  Post-
mitotic cells such as neurons are particularly vulnerable to the detrimental effects of 
damaged proteins as they are less efficient in selectively degrading and replacing 
damaged proteins.  This is evidenced by the accumulation of lipofusion inside the 
lysosomal compartment of post-mitotic cells which suggests an overload of normal 
chaperone capacity.  Compromised lysosomal degradative capacity prevents efficient 
mitochondrial recycling, leading to irreversible functional decay and cell death
141
.  Thus, 
promoting neuroprotection through induction of chaperone expression to help solubilize 
or clear protein aggregates become a rational therapeutic strategy.  A detailed 
understanding of chaperone-mediated protection and its therapeutic potential against 
protein misfolding and aggregation are reviewed in this section.   
Molecular Chaperones & Protein Folding 
Of all the molecules found in living organisms, proteins are the most important 
biological workhorses that carry out vital functions in every cell.  To accomplish their 
tasks, proteins must fold into a complex three-dimensional structure.  Although the amino 
acid sequence of a protein may provide the blueprint that dictates proper folding, the 
crowded (300 mg/ml protein) intracellular milieu places constraints on such ordered 
protein folding, thereby promoting misfolding and aggregation
142
.  To protect cells from 
the stress of misfolded proteins and guide proteins to their native states, molecular 
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chaperones are the first-line of supervision.  Molecular chaperones selectively bind to 
nascent polypeptides and partially folded intermediates, prevent premature aggregation 
and misfolding of de novo protein and promote the refolding or targeted degradation of 
damaged proteins
140
.  Molecular chaperones are an indispensable part of protein folding, 
targeting, transport, degradation and signal transduction
143
.   
In general, molecular chaperones are ubiquitous, highly conserved proteins, which 
function in a nucleotide-dependent manner, with an ATP-coupled conformational change 
to refold the substrate proteins
142
.  While some chaperones are constitutively expressed, a 
subset of chaperones known as heat shock proteins (Hsps) are regulated by environmental 
and physiological stresses 
144
.  The Hsps are classified into six main families based on 
their molecular mass (in kDa): Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and small Hsps 
which weigh less than 40 kDa.  While Hsps may be differentially expressed in tissues and 
subcellular compartments, Hsp90 has been shown to play an essential role in maintaining 
the functional stability and viability of cells under stress.  Specifically, Hsp90 promotes 
protein disaggregation and degradation through regulation of the transcription factor, heat 
shock factor-1 (HSF-1).  
In resting cells, Hsp90 binds to HSF-1 and maintains its inactive form in a 
monomeric state.  During a protein damaging stress, heat shock or inhibition of Hsp90, 
HSF-1 is released from the cytoplasmic chaperone/HSF-1 complex
145
.  The activation of 
HSF-1 proceeds through a multi-step pathway involving trimerization and 
phosphorylation, followed by its nuclear translocation.  The HSF-1 trimer binds to heat 
shock elements present in the promoters of heat shock genes and initiates a heat shock 
response (HSR), manifested in part by the production of Hsp70, Hsp40 and other 
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chaperones
145-146
.  Recent evidence implicates that pharmacological inhibition of Hsp90 
modulates aberrant protein interactions through an HSF-1-dependent stress response
147
.  
Thus, regulating chaperone expression through Hsp90 inhibition has become a promising 
therapeutic target for protein conformational disorders.   
Modulation of Hsp90 & Hsp70 in Neurodegenerative Disorders  
In response to many metabolic disturbances and injuries, cells mount a stress 
response via the induction of a variety of chaperones, most notably Hsp70.  Given that 
Hsp70 is usually not detectable under normal conditions in many cells, its induction 
suggests an upstream regulation by an Hsp90-mediated stress response.  Induction of 
Hsp70 via pharmacological inhibition of Hsp90 is well-documented in models of stroke, 
neurodegenerative disease and diabetes and forms a powerful endogenous protective 
system
148-150
.  Geldanamycin (GM), the first Hsp90 specific inhibitor, can decrease mis-
folded proteins and protein aggregates in models of neurodegeneration and stroke, 
through an HSF-1-dependent stress response.  Specifically, GM-mediated Hsp90 
inhibition increased expression of Hsp70 and disaggregated mutant tau and improved 
binding of tau to microtubules in a cell model of Alzheimer’s disease
151
.  A more potent 
derivative of GM, 17-AAG, showed similar results  where induction of Hsp70 correlated 
with degradation of mutant androgen receptor in polyglutamine diseases
152
.  Besides 
GM’s efficacy in neurodegeneration, induction of Hsp70 by GM also protects neural and 
cardiac cells against ischemic and toxic stress both in vitro and in vivo
153-154
.  Additional 
studies, independent of Hsp90 inhibition, have confirmed the beneficial effects of Hsp70 
induction in different models of nerve injury.  Arimoclomol, a nontoxic Hsp60/Hsp70 co-
inducer, has been shown to protect acute injury-induced and progressive motor-neuron 
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degeneration in mouse models of amyotrophic lateral sclerosis (ALS)
155
.  Muchowski et 
al found that Hsp70 and its co-chaperone Hsp40 suppressed oligomerization of mutant 
huntingtin and attenuated the formation of detergent-insoluble amyloid-like fibrils in a 
cellular model of Huntington’s disease
156
.  These studies suggest that the primary 
protective mechanism of Hsp70 is related to its chaperone function by promoting 
disaggregation of proteins, but other mechanisms have also been proposed.   
There might also be a relationship between protection by Hsp70 and oxidative 
injury.  Work by Polla and co-workers showed that Hsp70 induction protects cells from 
H2O2-induced alteration of ΔΨm
157
.  Similar observations were made in cultured glial 
cells where over-expression of Hsp70 increased glutathione levels and protected the cells 
from the H2O2, suggesting that Hsp70 might also protect antioxidant mechanisms
158
.  
Additionally, transgenic mice over-expressing Cu-Zn SOD (SOD1) showed prolonged 
expression of Hsp70 mRNA after focal and global ischemia in comparison to control
159-
160
.  Though the specific reason for this observation is unknown, altered oxidative stress 
with SOD1 over-expression may potentiate the expression of Hsp70.   
Overall, these studies support the hypothesis that the stress response provides an 
organism with a cellular process for self-preservation.  Hence, capitalizing on the natural 
cellular response to stress becomes an attractive therapeutic target for diseases that have 
multifactorial origins, such as DPN.   
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1.8 Dissertation Hypothesis 
Despite the prevalence and severity of DPN, current therapeutic approaches 
focusing on “diabetic specific” targets/pathways have met with limited translational 
success as the disease progression differs among individuals and does not occur with 
biochemical uniformity.  As reviewed above, the pathogenesis of DPN converges at 
mitochondrial dysfunction and oxidative stress-induced damage and resembles similar 
triggers seen in other neurodegenerative diseases.  Although the etiology of DPN is not 
causally linked to the accrual of any one specific mis-folded or aggregated protein, 
hyperglycemia can trigger oxidative modification of amino acids and increase glycation 
and oxidative stress that can contribute to protein aggregation
161-162
.  Thus, regulating 
chaperone expression in the context of DPN (Scheme 1-1) may mimic the broad 
cytoprotective effect seen in models of neurodegeneration.  In fact, in its early phase of 
development, Arimoclomol (formerly known as BRX220), increased both insulin 
sensitivity and glutathione peroxidase activity, induced Hsp60 and Hsp70 and improved 
NCV, in diabetic animals
163-164
.  Our lab has previously found that KU-32, a novobiocin-
derived small molecule inhibitor of Hsp90, effectively reversed preexisting sensory and 
electrophysiologic deficits of DPN in diabetic mice
165
.  Mechanistically, Hsp70 plays a 
central role in the neuroprotective efficacy of KU-32 as the drug was ineffective at 
reversing sensory deficits in diabetic Hsp70.1 and Hsp70.3 double knockout mice
165
.  
Evidence from these studies suggests that chaperone induction can promote a broad 
cytoprotective response that may be more efficacious against hyperglycemic insults than 
a highly selective single-target drug in DPN.   
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Scheme 1-1. Induction of molecular chaperones may be used as a novel drug target 
in DPN.  Given that the free radical theory of aging converges with mechanisms contributing to 
the etiology of DPN, the neuroprotective effects of chaperone induction reported from 
neurodegenerative disease studies may also be applicable in the context of DPN.  Moreover, the 
broad cytoprotective response from chaperone induction is indiscriminate against the biochemical 
inconsistency of disease progression in patients with DPN.  Thus, pharmacological induction of 
molecular chaperones may be an attractive, novel, “druggable” target to treat DPN.  
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With the deleterious effect of hyperglycemia, this dissertation aimed at 
systematically characterizing and antagonizing the effect of hyperglycemia on 
mitochondrial function in the peripheral nervous system, namely DRG sensory neurons 
and SCs, by inducing chaperone expressions using KU-32.  Specifically, this dissertation 
is divided into three areas of studies:  
1. Using stable isotope labeling of cells in culture (SILAC) as an unbiased and 
systematic assessment to study the effect of hyperglycemia on the 
mitochondrial proteome in DRG neurons and SCs. 
2. To antagonize hyperglycemic stress and promote neuroprotection in sensory 
neurons via pharmacological induction of chaperones using KU-32, a C-
terminal Hsp90 inhibitor.  
3. Enhance the neuroprotective properties of KU-32 by improving its interaction 
with the C-terminal Hsp90 binding site through structural modification. 
In this dissertation, we have chosen SILAC as an unbiased, quantitative approach 
to systematically study the effect of hyperglycemia in neurons and glial cells on a 
molecular level.  The rationale for choosing SILAC in this dissertation is reviewed 
below.   
Stable Isotope Labeling Using Amino Acids in Cell Culture (SILAC) - An 
Unbiased, Quantitative Proteomic Approach  
The most important and challenging technical task in proteomics is to accurately 
quantify the differences between two or more physiological states of a biological system.  
Many techniques in mass spectrometry involve creating a specific mass tag that can be 
recognized and quantified by the mass spectrometer.  These mass tags or quantitative 
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features can be introduced into proteins or peptides metabolically, chemically, or by 
spiked synthetic peptide standards (Figure 1-3)
166
.  In general, early introduction of 
quantitative features into the biological samples reduces the likelihood for quantification 
errors to occur.  In contrast, label-free quantification approaches aim to compare the mass 
spectrometric intensity of the proteolytic peptides between two samples directly, but 
harbor a higher chance of quantification errors as no internal control is available.  
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Figure 1-3. Common quantitative mass spectrometry workflows. Boxes in blue and yellow 
represent two experimental conditions. Horizontal lines indicate when samples are combined. 
Dashed lines indicate points at which experimental variation and thus quantification errors can 
occur. (Adapted from Bantscheff et al. Anal Bioanal Chem (2007) 389:1017–1031) 
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SILAC is a metabolic-based technique that has been used extensively to quantify 
relative protein changes in organellar proteomes.  A specific essential amino acid in the 
media such as 
12
C-Lys, is replaced by a non-radioactive, isotopically labeled form, 
13
C6-
Lys.  Two distinct cell populations are supplied media containing the different 
isotopically labeled forms of lysine and the labels are metabolically incorporated into 
newly synthesized proteins during cell divisions.  After the labeling period, one 
population of the cells serves as control while the other is subjected to treatment.  After 
harvesting, protein populations from control and experimental samples are mixed directly 
in a 1:1 mass ratio, processed and analyzed by mass spectrometry.  The molecular weight 
difference between the 
12
C-Lys and 
13
C6-Lys labeled proteins is 6 Da.  The relative 
protein abundance in the mixture is then measured as the differential intensity between 
12
C-Lys and 
13
C6-Lys peptide fragments in the mass spectra.  Generally, only 
incorporation of >95% is considered acceptable given that the labeled amino acid is the 
only available source for protein synthesis during incorporation.  This level of 
incorporation can be achieved by doubling of cell population and calculated using (1 – 
0.5
n
), where n denotes the number of population doublings
167
.  As primary SCs readily 
undergo multiple population doublings before they begin to phenotypically change, we 
used SILAC to characterize the effect of hyperglycemia on the SC proteome and 
determine how changes in the proteome affected functional measures of oxidative stress 
and mitochondrial bioenergetics (Chapter 2). However, this “standard” SILAC method is 
not suitable for neurons. 
Unlike dividing cells, neurons are post-mitotic cells and hence stable isotope 
incorporation can only be achieved by the rate of protein turnover
168
.  We tracked the 
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levels of label incorporation in individual proteins in DRG neurons for up to 4 weeks 
(Figure 1-4).  Despite the fact that the majority of proteins do indeed achieve significant 
levels of isotopic labeling, a subpopulation of the total quantified proteins was always 
partially labeled with less than 95% of incorporation.  The partially labeled protein can 
contribute to the quantification inaccuracy and hence, this dissertation employed a 
variation of SILAC, pulsed SILAC (pSILAC) as an alternative approach to study changes 
in the sensory neuron proteome.  Pulse-labeling with stable isotope has been used to 
measure protein turnover rates and can directly quantify the rate of protein translation on 
a proteome wide scale
169
.  Thus, pSILAC was employed to study the effect of 
hyperglycemia and KU-32 on DRG sensory neurons and determine how these changes in 
protein expression affected functional measures of oxidative stress and mitochondrial 
bioenergetics (Chapter 3). 
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Figure 1-4. Isotopic enrichment increased with duration of incorporation but 
did not reach equilibrium labeling. The DRG neurons were maintained and labeled in SILAC 
media for up to 4weeks.  Analysis of the proteome shows that only around 80% of the total 
protein quantified with 4 weeks of labeling has reached over 95% of SILAC incorporation.    
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Chapter 2: Hyperglycemia Alters the Schwann Cell 
Mitochondrial Proteome and Decreases Coupled Respiration 
in the Absence of Superoxide Production 
(Zhang, L., Yu, C., Vasquez, F.E., Galeva, N., Onyango, I., Swerdlow, R.H.,  Dobrowsky, R.T. 
(2010) Hyperglycemia Alters the Schwann Cell Mitochondrial Proteome and Decreases Coupled 
Respiration in the Absence of Superoxide Production. J. Proteome Res. 9, 458-471.) 
Abstract  
Hyperglycemia-induced mitochondrial dysfunction contributes to sensory neuron 
pathology in diabetic neuropathy.  Although Schwann cells (SCs) also undergo 
substantial degeneration in diabetic neuropathy, the effect of hyperglycemia on the SC 
mitochondrial proteome and mitochondrial function has not been examined.  Stable 
isotope labeling with amino acids in cell culture (SILAC) was used to quantify the 
temporal effect of hyperglycemia on the mitochondrial proteome of primary SCs isolated 
from neonatal rats.  Of 317 mitochondrial proteins identified, about 78% were quantified 
and detected at multiple time points.  Pathway analysis indicated that proteins associated 
with mitochondrial dysfunction, oxidative phosphorylation, the TCA cycle, and 
detoxification were significantly increased in expression and over-represented.  Assessing 
mitochondrial respiration in intact SCs indicated that hyperglycemia increased the overall 
rate of oxygen consumption but decreased the efficiency of coupled respiration.  
Although a glucose-dependent increase in superoxide production occurs in embryonic 
sensory neurons, hyperglycemia did not induce a substantial change in superoxide levels 
in SCs.  This correlated with a 1.9-fold increase in Mn superoxide dismutase expression, 
 
 
54 
which was confirmed by immunoblot and enzymatic activity assays.  These data support 
that hyperglycemia alters mitochondrial respiration and can cause remodeling of the SC 
mitochondrial proteome independent of significant contributions from glucose-induced 
superoxide production.  
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2.1 Introduction  
A severe and prevalent complication of diabetes is the development of diabetic 
peripheral neuropathy (DPN)
1
.  Hyperglycemia and poor control of blood glucose are 
precipitating events that initiate a series of complex and inter-related metabolic and 
vascular insults that underlie the etiology of diabetic neuropathy.  Two pathogenetic 
components that contribute to DPN are enhanced oxidative stress and mitochondrial 
dysfunction in both sensory neurons and Schwann cells (SCs)
2-3
.  Using cultured 
endothelial cells, Brownlee and colleagues were the first to suggest that increased 
mitochondrial superoxide production may be a unifying biochemical lesion that promotes 
hyperglycemia-induced increases in polyol synthesis, protein kinase C activity, protein 
modification by N-acetyl glucosamine, and formation of advanced glycation end products 
in endothelial cells
4-5
.  Consistent with this hypothesis, pharmacological interventions 
that decrease superoxide production and protein nitration in peripheral nerve improve 
morphological and physiological indices of nerve damage that contribute to diabetic 
neuropathy
6-9
. 
Although hyperglycemia can increase oxidative stress in mitochondria
10
,
 
it is 
unclear whether glucose-induced superoxide production may contribute to changes in 
mitochondrial protein expression and function.  SCs undergo substantial degeneration in 
DPN, but the broad effect of hyperglycemia on the SC mitochondrial proteome has not 
been examined.  To this end, we used stable isotope labeling of cells in culture (SILAC) 
to establish an unbiased and temporally dynamic assessment of the effect of 
hyperglycemia on the SC mitochondrial proteome.  SILAC has been used extensively for 
quantifying changes in organellar proteomes
11
 and requires at least two distinct 
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populations of SCs that are differentially labeled with, for example, 
12
C-Lys or 
13
C6-Lys.  
After 5-6 population doublings, the SCs readily incorporate the 
13
C6-Lys into their 
proteome such that at least 95% incorporation is obtained within 10 days
12
.  After the 
labeling period, one population of the cells serves as a control and the other is subjected 
to hyperglycemic stress for various periods of time. Cell lysates are then prepared, mixed 
together in a 1:1 mass ratio and specific subproteomes are enriched prior to analysis
13
. 
In the present study, SCs subjected to hyperglycemic stress for 2, 6, or 16 days 
exhibited an overall increase in the expression of numerous mitochondrial proteins 
associated with a broad range of biochemical functions.  Although hyperglycemia 
increased the expression of protein components of the respiratory chain, this correlated 
with a decreased mitochondrial efficiency toward ATP generation.  Concurrent measures 
of the rate of extracellular acidification indicated a shift toward glycolysis.  
Unexpectedly, we found that hyperglycemia did not significantly increase superoxide 
production either acutely (<6 h) or under conditions of more prolonged hyperglycemia (6 
days) using two fluorometric dyes.  The lack of glucose-induced superoxide generation 
may arise in part from an increase in mitochondrial Mn-SOD.  These data suggest that 
neonatal rat SCs are rather insensitive to glucose-induced superoxide generation in the 
mitochondria and that hyperglycemia affects the mitochondrial proteome independent of 
this marker of oxidative stress.  
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2.2 Experimental Section  
Schwann Cell Isolation & Metabolic Labeling.  
Schwann cells (SCs) were isolated as described and were cultured in low glucose 
(5.5 mM) DMEM that was custom prepared and conformed to Gibco DMEM (#12320), 
with the exception that L-arginine and L-lysine were omitted
12
.  Complete medium 
contained the specified isotopic forms of Lys or Arg, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 10% dialyzed FCS (dFCS, Atlas Biologicals, Fort Collins, CO), and 2 µM 
forskolin.  In experiments not requiring stable isotopes, the medium was supplemented 
with 84 mg/L 
12
C-Arg and 125 mg/L 
12
C-Lys (K0). For SILAC analysis, the cells were 
incubated in medium supplemented with 
12
C-Arg and U-[
13
C6]-L-Lys (
13
C6-Lys, K6).  
Primary SCs were used for 5 passages and were maintained in the labeling medium for at 
least 10 days prior to mass spectrometric analysis since this is the minimal labeling 
period necessary to obtain about 95% isotopic enrichment of the proteome
12
.  All the 
amino acids were prepared as 100× stock solutions in serum-free Arg/Lys deficient 
DMEM, sterile filtered and added to working volumes of medium.  Unlabeled amino 
acids were obtained from Sigma Chemicals (St. Louis, MO) and >98% isotopically 
enriched amino acids were a product of Cambridge Isotopes (Andover, MA); no 
correction for isotopic purity was made in the quantitative measures.  
Cell Fractionation for SILAC Analysis 
For proteomic analysis, 10 × 15 cm plates of SCs were expanded in K0 or K6 
complete medium yielding about 4 × 10
7 
cells per treatment.  Since it was necessary to 
passage the primary SCs twice to obtain a sufficient cell number to seed into the 10 
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plates, they have already been labeled to metabolic equilibrium.  At this point, the Lys 
concentration was also decreased to 62.5 mg/L in both the K0 and K6 cultures to 
conserve the metabolic label and forskolin was not added to the medium to avoid possible 
confounding effects due to the growth promoting activity of the drug.  After the cells 
became established, hyperglycemia was induced by adjusting the glucose concentration 
to 30 mM in the K6 or cultures (K0 in the reverse labeling experiment) and both sets of 
cells were incubated for 2, 6, or 16 days with a medium change every third day.  The 
cells were trypsinized, washed twice with ice-cold phosphate-buffered saline (PBS), and 
resuspended in 10 mL of mitochondrial isolation buffer (MIBA) containing 10 mM Tris-
HCl, pH 7.4, 1 mM EDTA, 0.2 M D-mannitol, 0.05 M sucrose, 0.5 mM sodium 
orthovanadate, 1 mM sodium fluoride, and 1× Complete Protease Inhibitors (Roche 
Diagnostics)
14
.  The cells were homogenized with the aid of a Teflon pestle and lysis was 
confirmed microscopically.  The protein concentration of each lysate was measured in 
quadruplicate using the Bradford assay and bovine serum albumin as the standard.  The 
coefficient of variation was determined for each set of quadruplicate measures and if the 
variability exceeded 5%, the protein assay was repeated for that set of samples.  The 
samples were then mixed together in a 1:1 mass ratio yielding 24–30mg of protein.  
Nuclei were isolated from the pooled lysates by centrifugation at 500× g at 4°C 
for 5 min.  The crude nuclei were washed with PBS and further purified as described 
below.  The remaining S1 supernatant was centrifuged at 8,000 × g for 10 min at 4°C, 
yielding the S2 supernatant and the heavy mitochondrial (HM) fraction.  The HM fraction 
was washed twice with MIBA and resuspended in 3 mL of 25% Nycodenz prepared in 10 
mM Tris-HCl, pH 7.4,1 mM EDTA, and 0.25 M sucrose.  Mitochondria were purified by 
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centrifugation at 50 000× g for 90 min at 4°C in a SW41 rotor over a discontinuous 
gradient of 40, 34, 30, 25 (HM), 23, and 20% Nycodenz as described
14
.  The 
mitochondria that sedimented at the 25-30% interface were recovered, the fraction was 
diluted with MIBA and the mitochondria pelleted by centrifugation at 10 000× g for 10 
min at 4 °C. The final mitochondrial pellet was resuspended in 0.1-0.15 mL MIBA.  
A cytosolic fraction was obtained from the S2 supernatant by centrifugation at 
100 000× g for 60 min at 4°C.  The resulting cytosol was concentrated at 4°C to less than 
0.5 mL using an Amicon Ultra filter device with a 10 000 nominal molecular weight 
limit.  Nuclei were purified following the procedure of Hwang et al
15
.  Briefly, the crude 
nuclei were resuspended in 20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1 mM EDTA, 1 
mM DTT, 0.25 M sucrose and mixed with an equal volume of 20 mM HEPES-KOH, pH 
7.5, 10 mM KCl, 1 mM EDTA, 1 mM DTT, 2.3 M sucrose (both buffers contained the 
Complete protease inhibitor cocktail).  The nuclei sample was then layered directly over 
the 2.3 M sucrose buffer and centrifuged at 60 000× g for 90 min at 4°C in a SW41 rotor.  
The nuclear pellet was washed with MIBA and resuspended in 0.1-0.15 mL of this 
buffer.  
To assess organelle enrichment, 3 µg of protein was fractionated by SDS-PAGE.  
After transfer to nitrocellulose, immunoblot analysis was performed using the following 
antibodies against marker proteins for mitochondria, MnSOD (Upstate Biotechnology, 
Lake Placid, NY) and prohibitin-1 (Neomarkers, Freemeont, CA); nuclei, p62 
nucleoporin (BD Transduction Laboratories, Lexington, KY); endoplasmic reticulum, 
GRP 78 (Santa Cruz Biotechnology, Santa Cruz, CA); and cytosol, lactate dehydrogenase 
(Sigma-Aldrich, St. Louis, MO).  
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Mass Spectrometry & Protein Identification  
Proteins were identified following one-dimensional SDS-PAGE coupled to RP-
HPLC linear quadrupole ion trap Fourier transform ion cyclotron resonance tandem mass 
spectrometry (GeLC-LTQ-FT MS/MS)
16
.  About 75-100 µg of protein was fractionated 
by SDS-PAGE, the proteins were visualized by staining the gel and the lane was cut into 
12-15 sections for in-gel tryptic digestion.  
The gel pieces were placed in silanized microfuge tubes and destained with 100 
mM ammonium bicarbonate in 50% acetonitrile
17
.  Following reduction (10 mM 
dithiothreitol at 55 °C for 1 h) and alkylation (55 mM iodoacetamide for 30 min in the 
dark at room temperature), the gel pieces were washed with 100 mM ammonium 
bicarbonate in 50% acetonitrile, dehydrated with 100% acetonitrile and dried.  The gel 
pieces were rehydrated on ice in a minimal volume of 25 mM ammonium bicarbonate, 
pH 7.5 containing 12.5 ng/µL Trypsin Gold (Promega Corp., Madison, WI), covered with 
a sufficient volume of 25 mM ammonium bicarbonate, pH 7.5 and the proteins were 
digested overnight at 37 °C.  The peptides were extracted from the gel particles with 5% 
formic acid in 100 mM ammonium bicarbonate and 5% formate in 100% acetonitrile.  
The combined supernatants were concentrated to ∼25 µL in a Speed-Vac prior to 
analysis.  
Peptides were separated on a microcapillary reverse-phase column (either 0.30 × 
150 mm, Pepmap C18, or 0.32 × 50 mm, MicroTech Scientific) at a flow rate of 5 -10 
µL/min with a linear gradient from 5 to 65% acetonitrile in 0.06% aqueous formic acid 
(v/v) over 55 min and the eluate was introduced into the LTQ-FT tandem mass 
spectrometer (ThermoFinnigan, Waltham, MA).  All experiments were performed in 
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data-dependent mode using dynamic exclusion with survey MS spectra (m/z 300-2000) 
acquired in the FT-ICR cell with resolution R = 25 000 at m/z 400 and accumulation to a 
target value of 5 × 10
5 
charges or a maximum ion accumulation time of 2000 ms.  The 
three most intense ions were isolated and fragmented with a target value of 2 × 10
3 
accumulated ions and an ion selection threshold of 3000 counts.  Dynamic exclusion 
duration was typically 200 s with early expiration if ion intensity fell below a S/N 
threshold of 2.  The ESI source was operated with a spray voltage of 2.8 kV, a tube lens 
offset of 170 V and a capillary temperature of 200 °C.  All other source parameters were 
optimized for maximum sensitivity of a synthetic YGGFL peptide ion at m/z 556.27.  
The MS/MS peak list was generated from the Xcalibur raw files using DTA 
Supercharge (v 1.17) (http://msquant. sourceforge.net).  The individual text files were 
linked to their corresponding LTQ-FT raw file and concatenated with the aid of an in-
house modified Perl script (MultiRawPrepare) originally obtained from the MSQUANT 
web address.  The concatenated file was submitted to Mascot (v. 2.1, Matrix Science, 
London, United Kingdom) and proteins were identified by searching a combined IPI 
mouse/rat (v3.26) database concatenated with their reverse sequences (188 450 total 
sequences).  Search parameters specified a maximum mass deviation of 10 ppm, a 
fragment tolerance of 0.5 Da, up to 1 missed cleavage, and carboxyamidomethylated 
cysteine as a fixed modification.  Variable modifications were set to consider protein N-
terminal acetylation, N-terminal pyro-glutamine, methionine oxidation, and the presence 
of 
13
C6-Lys.  The Mascot search results were imported into Scaffold Protein 
Identification software (v 2.0, Proteome Software, Portland, OR) and reanalyzed using 
the X! Tandem search algorithm to enhance and further validate peptide and protein 
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identification.  The peptide filter was set to a 95% confidence level and proteins validated 
by Scaffold at this confidence level or greater were considered identified without further 
verification.  Manual verification of other proteins, especially those identified by a single 
peptide, followed an acceptance criteria which required a fully tryptic peptide that was at 
least 7 amino acids in length, had a detected series of at least 4 consecutive y-ions or b-
ions, and a had Mascot ion score of 25 or greater at a mass deviation of ≤ 6 ppm (3 times 
the dispersion of the mass deviations).  Using these criteria for peptide identification, the 
overall false positive rate was estimated
18
 as <0.5% between the various time points used 
in the proteomic analyses.  
To assess the statistical mass accuracy between the experiments, the distribution 
of calibrated mass errors for all peptides initially identified in the search was obtained 
from MSQUANT and the errors were binned by 2 ppm intervals
19
.  The errors between 
the mitochondrial analyses followed a normal distribution and the average calibrated 
absolute mass deviation was 2.63 ± 0.21 ppm and the average dispersion was 1.97 ± 0.19 
ppm (Figure 2-1).  
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Figure 2-1. Distribution of Mass Errors and Estimation of Statistical MassAccuracy.  
At each time point, the calibrated mass errors (ppm) for all the peptides identified from the 
mitochondrial fractions by Mascot were obtained from the MSQUANT peptide report.  Mass 
errors were binned to a width of 2 ppm and the number of peptides per bin counted.  Data shows 
the Gaussian nature of the distribution of mass deviations and the average dispersion was 1.97+ 
0.19 ppm. 
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Protein Quantification, Statistical & Bioinformatic Analyses  
The expression ratio of individual peptide pairs was obtained using MSQUANT
20
.  
However, it was also necessary to manually quantify peptide pairs and verify a subset of 
the MSQUANT results using peak intensities from Xcalibur software (v2.0 SR1).  If 
similar peptides of different charge states were detected, only the peptide with the highest 
ion score was counted toward identification and quantified.  Similarly, redundant 
peptides containing a modification were only counted toward identification and 
quantified if an unmodified peptide was not detected.  If multiple peptide pairs were 
quantified for the same protein, an overall protein expression ratio was taken as the 
average of these measures and the standard deviation was determined.  The protein lists 
from MSQUANT were imported into Protein Center (Proxeon Bioinformatics, Odense, 
Denmark) and redundant mouse-rat orthologs and database entries were removed after 
clustering at 60% homology.  The anchor protein used for clustering a given group of 
proteins is indicated in Supplementary Tables 1-3 (Appendix).  
As previously reported, 3 times the average standard deviation of all the 
expression ratios at a given time point was assigned as the threshold for indicating a 
significant change
21
.  For example, of 1251 proteins identified at all times points in the 
mitochondrial fractions, 991 (79%) were quantified and 556 were quantified by ≥2 
unique peptides.  The average standard deviation obtained in these three separate 
experiments was 0.111 ± 0.02, indicating that the analytic variability was tightly 
clustered at about 11%.  Using the above criterion, proteins whose expression ratios were 
<0.67 or >1.33 were defined as showing a significant change.  
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Proteins were automatically annotated with respect to cell localization using 
Protein Center and via manual annotation from the SwissProt database. Bioinformatic 
analyses were performed using Ingenuity Pathway Analysis (v 7.0, Ingenuity Systems, 
Redwood CA) and BinGO
22
.  After setting a bidirectional 1.3 fold change as the 
threshold, the program identified statistically over or under represented molecular 
networks.  Pathways with p < 0.001 using the HyperGeometric test after correcting for 
multiple term testing by the Benjamini and Hochberg False Discovery Rate (B-H FDR) 
were deemed enriched.  
Mitochondrial Respiration & Extracellular Acidification Measures  
The rates of O2 consumption (OCR) and extracellular acidification (ECAR) were 
assessed on intact SCs using an Extracellular Flux Analyzer (Seahorse Biosciences, 
North Billerica, MA).  Extracellular flux analysis is a non-invasive assay which uses two 
calibrated optical sensors which directly measure OCR and ECAR in cells that remain 
attached to the culture plate.  This technique avoids variability associated with 
trypsinization and mechanical stirring of the cells to determine OCR.  Primary SCs were 
treated with 5.5 mM or 30 mM glucose for 3 days and baseline respiration was 
determined.  Respiratory chain inhibitors were sequentially injected into the wells and 
ATP-coupled oxygen consumption was calculated as the oxygen consumption rate 
sensitive to 1 µM oligomycin, an ATP synthase inhibitor, after correcting for non-
mitochondrial respiration.  Proton leak was calculated as the mitochondrial rate 
insensitive to oligomycin, after correcting for non-mitochondrial respiration.  The 
maximal uncoupled respiration rate was determined by depolarizing the mitochondrial 
membrane potential with 1 µM FCCP (carbonylcyanide-4-(trifluoromethoxy)-
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phenylhydrazone) and non-mitochondrial respiration was determined as the activity 
remaining after inhibition of complexes 1 and 3 with 1 µM rotenone and 1 µM 
myxothiazol, respectively.  Changes in ECAR are an indirect assessment of glycolytic 
activity due to lactic acid production and proton extrusion and were measured concurrent 
with oxygen consumption
23
.  After the measures, the cells were harvested, protein 
concentration of each well was determined and experimental rate values were normalized 
to protein content.  
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Superoxide Assessment & Mn-SOD Activity Assay  
Superoxide levels were measured by following the oxidation of dihydroethidine 
(Invitrogen-Molecular Probes, Carlsbad, CA) to ethidium
24
.  SCs were seeded at 1 × 10
4 
cells per well in 96-well plates and were treated with 5.5 mM or 30 mM glucose for the 
indicated times once reaching about 90% confluency.  At the end of the incubation, the 
cells were incubated with 15 µM dihydroethidine for 15 min at 37 °C.  The cells were 
washed with PBS and the ratio of ethidium (excitation 530 nm, emission 590 nm) to 
dihydroethidine (excitation 485 nm, emission 530 nm) was determined with the cells 
attached to the plate using a fluorescence spectrometer.  
For assessing superoxide production using MitoSOX Red
25
, SCs were grown in 
low glucose DMEM in six well plates until confluent.  Cells were incubated in medium 
containing 5.5 mM or 30 mM glucose for 6 days and the cells were washed once with 
OPTI-MEM medium.  MitoTracker Green (80 nM) was added to each well and after 10 
min, 2.25 µM MitoSOX Red was added into the wells and the cells incubated for an 
additional 10 min.  The cells were washed twice with fresh OPTI-MEM medium prior to 
imaging on an Olympus 3I Spinning Disk confocal microscope using excitation/ emission 
wavelengths of 575/624 nm (MitoSox Red) and 494/531 nm (MitoTracker Green).  As a 
positive control, some cells were treated with 1.8 µg/mL Antimycin A in OPTI-MEM 
medium with 1% BSA for 25 min.  Fluorescence intensity of the red and green signals of 
at least 200 cells per treatment was obtained using CellProfiler and CellProfiler Analyst 
image analysis software.  
To assess manganese superoxide dismutase (Mn-SOD) activity, SCs were seeded 
into 10 cm plates and treated with 5.5 mM or 30 mM glucose for the indicated times after 
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reaching about 90% confluency.  The cells were trypsinized and three plates per treatment 
were combined to isolate a heavy mitochondrial fraction as described above.  Mn-SOD 
activity was determined as described by the manufacturer (Dojindo Molecular 
Technologies, Gaithersburg, MD) using 0.5-3µg of the heavy mitochondrial fraction.  To 
inhibit Cu/Zn SOD, the protein was pre-incubated with 2 mM KCN for 30 min at 4 °C 
prior to assaying for MnSOD activity
14
. 
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2.3 Results  
Analysis of the SC Organellar Fractions 
Although the primary focus of the study was on assessing the effect of 
hyperglycemia on altering the mitochondrial proteome, nuclei and cytosolic fractions 
were also isolated as described in the Experimental Methods (Figure 2-2A).  Organelle 
purity was assessed following SDS-PAGE and immunoblot analysis for the presence of 
established protein markers of nuclei, mitochondria, endoplasmic reticulum and cytosol 
(Figure 2-2B).  As expected, the mitochondrial fraction was enriched in the inner 
mitochondrial membrane and matrix proteins, prohibitin 1 and MnSOD.  Neither marker 
protein for cytosol (lactate dehydrogenase) or nuclei (p62 nucleoporin) was detected in 
the purified mitochondrial fraction but it did remain contaminated with endoplasmic 
reticulum.  Indeed, we repeatedly found GRP78 in most fractions and it proved difficult 
to remove from the mitochondrial fraction by using either Nycodenz or Percoll 
discontinuous gradients.  Although GRP78 is a resident protein of the endoplasmic 
reticulum, it is also secreted from the organelle which may contribute to its cytosolic 
localization.  
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Figure 2-2. Assessment of organelle purity.  K0 and K6 primary SCs were cultured for 
16 days in 30 mM glucose, lysates were prepared and mixed together in a 1:1 mass ratio.  
Nuclear, mitochondrial and cytosolic fractions were isolated and (A) 75 µg of protein was 
separated by SDS-PAGE for proteomic analysis or (B) 3 µg was subjected to immunoblot 
analysis for the indicated organelle marker.  
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Hyperglycemia Has Temporally Distinct Effects on Nuclear & Mitochondrial 
Protein Expression  
To perform a temporal analysis of the effect of hyperglycemia on the SC 
proteome, metabolically labeled cells (K6) were treated with 30 mM glucose for 2, 6, or 
16 days while unlabeled control cells (K0) were maintained in 5.5 mM glucose at each 
time point.  This time course was chosen to model the effect of acute and more chronic 
hyperglycemia on the primary SCs.  Although triple labeling can be performed for 
temporal analyses by SILAC
26
, we only used 
13
C6-Lys as a single metabolic label and 
performed three separate experiments to cover the time course.  Mitochondrial, nuclear 
and cytosolic proteins were separated by SDS-PAGE, in-gel digested with trypsin and the 
peptides were analyzed by GeLC-LTQ-FT MS/MS.  The acquired mass spectra were 
searched against a combined mouse-rat IPI database and we identified 1673 proteins from 
the various cell fractions at all time points and 1198 (71.6%) of these proteins were 
unique.  
Analysis of the nuclear fraction identified 332 total proteins, of which, 64% were 
detected at 2 or more time points (Figure 2-3A).  Among the total proteins identified in 
this fraction, resident nuclear proteins were identified by their gene ontology (GO) 
annotation and 213 nuclear proteins were quantified using 1145 peptides (Supplementary 
Table 1-1, Appendix).  In order to broadly compare the temporal effect of hyperglycemia 
on the nuclear proteome, the quantified proteins were ranked by their expression ratio and 
plotted versus protein number (Figure 2-3B) or the expression ratios were binned and the 
percent of proteins per bin was determined (Figure 2-3C).  Increases in nuclear protein 
expression were rather similar between 2 and 16 days of hyperglycemia with 40% and 
 
 
72 
51% of the quantified proteins showing a statistically relevant increase, respectively.  In 
contrast, 6 days of hyperglycemia led to 35% of the nuclear proteins showing a decreased 
expression.  On the other hand, hyperglycemia had little effect on proteins identified in 
the cytoplasmic fraction (Supplementary Table 1-2, Appendix).  Although the majority of 
cytoplasmic proteins showed no significant change after 2 (91.7%) or 6 (84.0%) days of 
hyperglycemia, about 34% of the quantified proteins showed an increased expression 
after 16 days (Figure 2-3D & E).  
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Figure 2-3. Hyperglycemia has differential effects on the nuclear and cytoplasmic 
proteomes.  SCs were incubated in medium containing 5.5 mM (K0) or 30 mM (K6) medium for 
2, 6, or 16 days and nuclear and cytoplasmic fractions were analyzed by GeLC-LTQ-FT MS/MS.  
(A) Venn diagram of number and percent of annotated nuclear proteins identified at each time 
point.  To compare the effect of 2, 6, or 16 days hyperglycemia on the (B, C) nuclear or (D, E) 
cytoplasmic proteomes, the expression ratios were (B, D) plotted versus protein number or (C, E) 
binned by 0.2 units and expressed as a percent of the total quantified proteins.  Line indicates 
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three times the standard deviation of the analytic variability and proteins between the lines did not 
show a significant change.   
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BinGO was used to determine if any biological processes were over-represented 
among the nuclear proteins that showed a significant change in their expression ratio after 
hyperglycemic stress
22
.  Proteins affecting chromatin regulation, DNA remodeling and 
transcription were over-represented after 2 days of hyperglycemia (Figure 2-4A).  This 
result was consistent with the pathway analysis which found that the top two molecular 
networks affected by hyperglycemia were associated with increases in mRNA 
processing, splicing and modification and DNA repair (Figure 2-4B).  Conversely, 
proteins associated with protein transport, biosynthesis and metabolism were either 
marginally decreased or unchanged, especially since the majority of these proteins are 
cytoplasmic.  
Mitochondrial proteins were identified by their GO annotation in Protein Center 
and by filtering against a reference set of 1,022 mouse mitochondrial proteins 
downloaded from the MitoP2 project (http://141.39.186.157:8080/mitop2/, last updated 
Nov. 2008).  Using this approach, we identified 317 unique proteins that either reside or 
are associated with mitochondria and detected 242 proteins (76.3%) at two or more time 
points (Figure 2-5A).  Using 1,599 peptides, 248 proteins were quantified but the 
detection of only Arg-containing tryptic peptides negated quantification of the remaining 
69 proteins.  Only 16 (5.0%) non-quantifiable mitochondrial proteins were identified by a 
single peptide at a single time point and the ion scores and MS
2 
spectra for these peptides 
are shown in Supplementary Table 1-3 (Appendix).  
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Figure 2-4. Identification of functional classes of nuclear proteins affected by 
hyperglycemia.  (A) Quantified proteins were grouped based upon their annotated function.  The 
expression ratios of all proteins associated with a function were averaged and the line indicates 
three times the standard deviation of the analytic variability associated with the quantitation.  
Categories above or below these limits define a significant change in expression.  The number of 
quantified proteins per category is indicated in the legend.  Significant differences between time 
points were determined using a one-way ANOVA and Tukey’s post hoc test. *, p < 0.05 
compared to 2 days, ˆ, p < 0.05 compared to 6 days.  (B) Top two molecular networks affected 
after 2 days of hyperglycemia were identified using Ingenuity Pathway Analysis, merged and 
graphically presented to highlight the increase in proteins regulating mRNA processing and the 
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decrease in proteins regulating protein synthesis, metabolism and transport.  Gene names are 
identified in Supplementary Table 1-4 (Appendix).  
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After 2 or 6 days of hyperglycemia, approximately 90% of all mitochondrial 
proteins showed a statistically relevant increase (Figure 2-5B).  However, about 21% of 
the proteins increased expression ≥1.9-fold after 6 days of hyperglycemia compared to 
only 7.0% and 1.1% after 2 or 16 days of glycemic stress (Figure 2-5C).  Indeed, after 16 
days of hyperglycemia, only 56% of the mitochondrial proteins increased above 1.3 fold.  
The analytic and biologic confidence of these changes is strengthened by the 
observation that when the SILAC experiment was reversed (K6 cells as control and K0 
subjected to 6 days of hyperglycemia), the overall effect on the mitochondrial proteome 
was similar (Figure 2-5B).  Second, immunoblot analysis for prohibitin 1 showed a 
similar increase in expression after 6 days of hyperglycemia as was determined by the 
SILAC analysis (Figure 2-6).  Additionally, proteins known to exist in a 1:1 subunit 
stoichiometry showed similar changes at each time point
27
.  For example, after 2 days of 
hyperglycemia, quantitation of 6-10 peptides identifying the α and β subunits of ATP 
synthase indicated an increase of 1.66 ± 0.11 and 1.49 ± 0.11, respectively.  Agreement 
between changes in ATP synthase subunit levels was also preserved after 6 (1.50 ± 0.09 
and 1.59 ± 0.11) or 16 days (1.30 ± 0.12 and 1.369 ± 0.11) of hyperglycemia.  Similarly, 
the relative change in the α and β subunits of the E1 component of the pyruvate 
dehydrogenase were tightly correlated (Supplementary Table 1-3, Appendix).  Lastly, the 
average expression ratio of all contaminating non-mitochondrial proteins did not show a 
statistically relevant change after 6 (176 proteins) or 16 (228 proteins) days of 
hyperglycemia although a 1.42 fold increase was noted after 2 days of hyperglycemia 
(145 proteins).   
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Figure 2-5. Temporal Profile of the Effect of Hyperglycemia on the Mitochondrial 
Proteome.  SCs were incubated in medium containing 5.5 mM (K0) or 30 mM (K6) medium for 
2, 6, or 16 days and mitochondrial fractions were analyzed by GeLC-LTQ-FT MS/MS.  (A) Venn 
diagram of number and percent of annotated mitochondrial proteins identified at each time point.  
To compare the effect of 2, 6, or 16 days hyperglycemia on the mitochondrial proteome, the 
expression ratios were (B) plotted versus protein number or (C) binned by 0.2 units and expressed 
as a percent of the total quantified proteins.  Reverse label indicates results from an experiment 
where control cells were labeled in K6 medium.  Line indicates three times the standard deviation 
of the analytic variability and proteins between the lines did not show a significant change.  
 
 
 
80 
 
 
Figure.2-6 Hyperglycemia Increased Prohibitin 1. SCs were incubated with 5.5 mM 
(K0) or 30 mM (K6) glucose for 6 days. (A) Spectra show MS1 scan indicating a 1.6 fold 
increase for the prohibitin peptide AATFGLILDDVSLTHLTFGK. (B) The expression of 
prohibitin 1 from a heavy mitochondrial fraction obtained from SCs subjected to hyperglycemia 
for the indicated time. β-Actin was used as a loading control. 
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Hyperglycemia Increased the Expression of Proteins Contributing to 
Mitochondrial Dysfunction & Decreases the Efficiency of Oxidative 
Phosphorylation.  
The above analysis strongly suggests that the mitochondrial proteome undergoes a 
marked increase in protein expression during hyperglycemic stress.  This response would 
suggest that proteins involved in coordinated metabolic functions such as glucose 
metabolism, oxidative phosphorylation, lipid metabolism, stress response mediators and 
gene expression may respond in a concerted manner.  Clustering the mitochondrial 
proteins by functional class showed that the quantified components of the mitochondrial 
respiratory chain exhibited a significant increase in expression after 2 and 6 days of 
hyperglycemia (Figure 2-7A).  This corresponded with a 1.6-to 1.8-fold increase in 
components of the TCA cycle which provides the reducing equivalents utilized by the 
respiratory chain.  However, after 16 days, there was a significant decline in expression 
of proteins associated with the TCA cycle as well as with complexes I and V.  
To identify the top metabolic processes affected by hyperglycemia over time, the 
data sets were subjected to pathway analysis.  Mitochondrial dysfunction, oxidative 
phosphorylation and the TCA cycle were among the top over-represented canonical 
pathways after 2 or 6 days of hyperglycemia (Figure 2-7B).  These data are consistent 
with previous work which demonstrated that hyperglycemia increased the transcript 
levels for components of oxidative phosphorylation
28
.  Proteins annotated to 
mitochondrial dysfunction were linked primarily to the regulation of respiration and 
detoxification of reactive oxygen species.   
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Figure 2-7. Temporal effect of hyperglycemia on functional classes of mitochondrial 
proteins.  (A) Quantified proteins were grouped based upon their annotated function.  The 
expression ratios of all proteins associated with a function were averaged and the line indicates 
three times the standard deviation of the analytic variability associated with the quantitation.  
Categories above or below these limits define a significant change in expression.  The number of 
quantified proteins per category is indicated in the legend. Significant differences between time 
points were determined using a one-way ANOVA and Tukey’s post hoc test. #, p < 0.05 
compared to 2 days, *, p < 0.05 compared to 2 and 6 days.  FAM, fatty acid metabolism; Ox 
Phos, oxidative phosphorylation.  (B) Top over-represented toxicologic functions were identified 
using Ingenuity Pathway Analysis.  Ordinate values are -log of the Benjamini-Hochberg False 
Discovery Rate p-value.  
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Since proteins associated with the TCA cycle and oxidative phosphorylation were 
increased, this suggested that hyperglycemia was affecting mitochondrial activity.  SCs 
were subjected to hyperglycemic stress for three days and the rate of oxygen 
consumption was measured over 2 h using intact SCs.  Since the oxygen consumption 
rates (OCR) and extracellular acidification rates (ECAR) are affected by metabolic 
activity and the number of cells
23
, both indices were normalized to total protein.  
Hyperglycemia increased the overall rate of oxygen consumption and part of this effect 
was related to a 1.5 fold increase in non-mitochondrial oxygen consumption by 
hyperglycemia: basal OCR minus rotenone + myxothiazol insensitive OCR (Figure 2-
8A).  Coupled respiration and proton leak were determined using the ATP synthase 
inhibitor, oligomycin. In the presence of 5.5 mM glucose, SCs devoted 88.2 ± 16.6% of 
their mitochondrial respiration for ATP production and 11.8% to proton leak.  Under 
hyperglycemic conditions, ATP coupled respiration decreased to 64.5 ± 12.2% and 
proton leak increased to 35.4%.  Thus, hyperglycemia decreased mitochondrial efficiency 
by uncoupling oxygen consumption from ATP production.  Consistent with a decrease in 
the efficiency of oxidative phosphorylation, hyperglycemia increased extracellular 
acidification by 2.1 ± 0.4 fold, suggesting an increase in the rate of glycolysis (Figure 2-
8B)
29
. 
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Figure 2-8. Hyperglycemia increased the oxygen consumption rate and extracellular 
acidification.  SCs were subjected to hyperglycemic stress for 3 days and (A) the oxygen 
consumption rate (OCR) and (B) extracellular acidification rate (ECAR) were measured in intact 
cells using an Extracellular Flux Analyzer.  Oligomycin, FCCP and rotenone/myxothiazole were 
added at the indicated times to determine the rate of proton leak and O2 coupled ATP production.  
Respiration experiments were repeated three times and the results presented are four replicate 
measures per time point from one representative experiment.  
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Hyperglycemia Increased the Expression of MnSOD but Not the Production of 
Superoxide Anion  
Proteins annotated as mediating mitochondrial detoxification responses showed 
the largest increase as a class after 6 days of hyperglycemia.  Among this group, SILAC 
analysis indicated that MnSOD (Figure 2-9A) expression increased about 2.0 fold after 6 
days of hyperglycemia.  The increase in Mn-SOD was specific since a similar change 
was not observed in the cytosolic Cu/Zn SOD (Figure 2-9B).  These differences were 
confirmed in separate experiments by immunoblot analysis as well. SCs were treated 
with 5.5 mM or 30 mM glucose for 2-6 days, and heavy mitochondrial and cytosolic 
fractions were obtained.  Curiously, the magnitude of the increase in MnSOD in the 
heavy mitochondrial fraction seemed slightly greater by immunoblot analysis but was 
nonetheless consistent with that observed in the purified mitochondria (Figure 2-9C & E).  
Confirming the mass spectrometric analysis, hyperglycemia did not increase cytosolic 
levels of CuZn SOD (Figure 2-9D).  Consistent with our proteomic data, MnSOD activity 
also increased by 2-2.5 fold after 4-6 days of hyperglycemia (Figure 2-10A).  Lastly, to 
rule out that the observed changes were the result of osmotic stress, SCs were incubated 
with 30 mM L-glucose or mannitol for 6 days and a heavy mitochondrial fraction was 
isolated.  No change was observed in the expression of Mn-SOD and prohibitin 1 (data 
not shown).  Since L-glucose is not metabolized, these data suggest that osmotic stress 
was not sufficient to alter mitochondrial protein expression.  
Glucose-induced production of superoxide within mitochondria has been 
suggested to be a key biochemical feature of glucotoxicity
9,30
.  Surprisingly, no 
significant change in total cellular superoxide levels was observed in the SCs even after 
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prolonged hyperglycemia (Figure 2-10B).  On the other hand, previous studies in 
embryonic sensory neurons cultured for several days in vitro have suggested that glucose-
induced superoxide generation may occur shortly after exposure to high glucose
24
.  
However, even after 4-6 h of hyperglycemia, we observed no significant increase in 
superoxide generation (data not shown).  Since the above study monitored the cellular 
conversion of hyroethidine to ethidium, we next used the mitochondrially targeted 
derivative of hydroethidine, MitoSox Red along with co-staining for mitochondria using 
MitoTracker Green to more directly visualize if hyperglycemia increased superoxide in 
the mitochondria.  Similar to the above results, six days of hyperglycemia did not 
significantly enhance mitochondrial superoxide production (Figure 2-10 C & D).  
However, the mitochondria were actively capable of producing this molecule since a 
brief incubation with antimycin A clearly increased mitochondrial superoxide generation 
as shown by the increase intensity of the yellow fluorescence. 
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Figure 2-9. MnSOD but not Cu/Zn SOD Increased with Hyperglycemic Stress.  SCs 
were incubated with 5.5 mM (K0) or 30 mM (K6) glucose for 6 days and mitochondrial and 
cytosolic fractions were isolated.  Spectra show MS1 scans indicating (A) an increase in intensity 
of a representative labeled peptide from mitochondrial MnSOD but (B) no change in intensity of 
a labeled peptide for cytosolic Cu/Zn SOD.  The expression of (C) MnSOD or (D) CuZn SOD 
was determined by immunoblot analysis using a heavy mitochondrial fraction and cytosolic 
fraction prepared from SCs were treated for the indicated days with 30 mM glucose.  (E) MnSOD 
expression was normalized to β-actin levels and the average of two separate experiments is 
expressed as a fold control.   
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Figure 2-10. Acute hyperglycemia increased MnSOD activity but not superoxide 
production.  (A) SCs were incubated with 5.5 mM or 30 mM glucose for the indicated time and a 
heavy mitochondrial fraction was isolated.  MnSOD activity was determined after a 30 min 
preincubation with 2 mM NaCN to inhibit residual Cu/Zn SOD activity and results are the mean 
± SEM from three separate experiments.  *, p < 0.05 compared to control.  (B) SCs were 
incubated with 5.5 mM or 30 mM glucose for the indicated time and cellular superoxide levels 
were determined after the addition of 3 µM dihydroethidine.  Results are the mean of four 
experiments perform with 8 replicates each and are expressed as a percent of control.  (C) SCs 
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were incubated with 5.5 mM or 30 mM glucose for 6 days, treated with MitoSox Red and 
MitoTracker Green and mitochondrial levels of superoxide were visualized by confocal 
microscopy.  Incubation with Antimycin A served as a positive control for mitochondrial 
superoxide generation.  (D) Quantitative image analysis of superoxide levels.  Results are from a 
representative experiment performed twice and are the mean ± SEM from at least 200 cells per 
treatment.  *, p < 0.05 versus low and high glucose treatments.  
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2.4 Discussion  
To date, few studies have used SILAC as an approach to examine the effect of 
hyperglycemic stress on primary cells that regulate glucose uptake or contribute to 
diabetic complications.  However, the utility of SILAC in identifying novel proteins that 
may contribute to diabetes is highlighted by a recent report showing that cultured 
myotubes from extremely obese women secreted almost 3 times more myostatin than 
myotubes obtained from lean or moderately obese patients
31
.  Additionally, SILAC has 
been used to characterize the phosphoproteome of the insulin signaling pathway
21,32-33
.  
In the present study, we provide the first quantitative characterization of the temporal 
effect of hyperglycemia on the proteome of cultured primary SCs using SILAC.  
One benefit of the SILAC approach is that the isotopically enriched amino acid is 
not preferentially incorporated into a given sub-proteome if a sufficient labeling period is 
performed.  Therefore, we characterized the broad effect of hyperglycemia on the SC 
proteome by isolating cytoplasmic, nuclear and mitochondrial subcellular fractions.  
After 2 days of hyperglycemia, nuclear proteins affecting chromatin regulation, DNA 
remodeling and transcription increased but the mean expression ratio was 1.03 for all the 
proteins identified in the nuclear fraction, suggesting a limited global effect.  Similarly, 
hyperglycemia had little effect on altering cytoplasmic proteins at all time points, but one 
cytoplasmic enzyme worth noting is aldose reductase.  It is well recognized that an 
increase in aldose reductase activity contributes to the pathophysiology of diabetic 
neuropathy
34-35
.  Although we did not assess aldose reductase activity in the present 
study, the unbiased identification of aldose reductase indicated that its expression was 
unaffected by hyperglycemic stress in the cultured SCs.  This lack of change in aldose 
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reductase expression is consistent with previous reports that its mRNA level is not 
induced in hyperglycemic rat SCs
36
 and that aldose reductase immunoreactivity does not 
increase in SCs of diabetic rat sciatic nerve
37
. 
In large part, hyperglycemia had the greatest effect on the SC mitochondrial 
proteome since the average expression ratio was 1.51 for all proteins identified in the 
mitochondrial fraction.  This result is consistent with previous reports that numerous 
mitochondrial proteins were increased in hearts obtained from OVE26 mice that were 
diabetic for 18 weeks
38
 and in cardiomyocytes from acutely hyperglycemic rats
39
.  For 
specific succinyl CoA synthetase increased to a similar level in both the 
hyperglycemically stressed SCs and in diabetic rat heart mitochondria
38
.  Interestingly, 
we also observed an increase in up-regulated during skeletal muscle growth protein 5, a 
poorly characterized mitochondrial protein which associates with ATP synthase
40
.  This 
protein is also known as diabetes-associated protein in insulin sensitive tissues (DAPIT) 
since its mRNA decreased in muscle but not brain of diabetic rats
41
.  Thus, DAPIT may 
be a novel glucose-responsive protein that affects mitochondrial function in diabetic 
tissues.  Although we did not explore the mechanism by which high glucose caused such 
a broad increase in mitochondrial proteins, evidence exists for an increase in 
mitochondrial biogenesis in diabetic heart
38
.  Consistent with the possibility of an acute 
increase in mitochondrial biogenesis, mitochondrial transcription factor A is critical for 
the replication of mitochondrial DNA,
42
 and it was increased approximately 1.7 fold after 
2 or 6 days of hyperglycemia.  
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A recent report has demonstrated that diabetes induced a tissue-specific 
remodeling of the mitochondrial proteome in organs derived from 6-week old diabetic 
Akita mice that did not necessarily correlate with changes in mitochondrial function
43
.  
For example, despite a diabetes-induced increase in proteins involved in oxidative 
phosphorylation and the TCA cycle, no changes were observed in mitochondrial 
respiration in organelles obtained from liver, brain or kidney
43
.  However, in heart 
mitochondria, diabetes decreased the expression of proteins involved in oxidative 
phosphorylation and the TCA cycle and this correlated with a decrease in mitochondrial 
respiration.  These data highlight the issue that hyperglycemic stress can differentially 
affect the mitochondrial proteome and respiratory activity.  Since it is difficult to model 
chronic diabetes in a cell culture model, the overall increase in the SC mitochondrial 
proteome in our acute cell culture model may more reflect early protective responses to 
hyperglycemic rather than chronic damage.  Proteomic analysis of mitochondria isolated 
from dorsal root ganglia and sciatic nerve of animals rendered diabetic for various 
durations will provide further insight into the utility of the primary cell models to address 
more mechanistic issues contributing to changes in the proteome associated with 
protective versus degenerative responses.  
Despite the increase in mitochondrial respiratory proteins in heart mitochondria 
from diabetic mice, the respiratory control ratio was actually lower but the coupling of 
ATP production and oxygen consumption (P/O ratio) was not affected
38
.  Although 
mitochondrial respiration is often measured using purified mitochondria, the use of the 
XF24 Extra-cellular Flux Analyzer allowed us to use intact SCs to assess both 
mitochondrial and non-mitochondrial effects of glucose on oxygen consumption and 
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medium acidification.  In 5.5 mM glucose, ∼88% of the mitochondrial oxygen 
consumption was coupled to ATP production in intact SCs.  In contrast, hyperglycemia 
decreased the amount of ATP-coupled oxygen consumption by 27% and increased the 
extent of proton leak 3-fold.  The decreased efficiency and increased proton leak suggests 
that hyperglycemia is lowering the P/O ratio, but we did not directly assess this 
parameter.  Although our data does reflect the physiological response of the intact SCs to 
high glucose, it is difficult to directly compare these data with the lack of a change in the 
P/O ratio observed in mitochondria from diabetic heart
38
 due to the different experimental 
conditions.  Lastly, although glycolytic proteins did not increase in expression after 2-6 
days of hyperglycemia, 3 days of hyperglycemia increased ECAR, which is an indirect 
measure of glycolytic activity (lactic acid production) and non-glycolytic acidification 
from CO2 production
23
.  These data suggest that the cultured SCs are highly glycolytic 
even in the absence of protein upregulation.  
The putative physiological role of proton leak is to contribute to the uncoupling of 
electron transport from ATP synthesis (heat generation) and decrease oxidative stress by 
reactive oxygen species
44
.  Although increases in the mitochondrial membrane surface 
area and phospholipid composition can affect the basal leak rate, changes in the 
expression of the adenine nucleotide transporter 1 protein (ANT1) can also contribute to 
mild uncoupling
44
.  Previous data has shown that a 1.7 fold increase in ANT1 can 
increase proton leak by about 1.5 fold in isolated mitochondria
45
.  We found that 
hyperglycemia induced a 1.5 fold increase in ANT1 expression after 2-6 days 
(Supplementary Table 1-3, Appendix) and this correlated with an increased proton leak 
from a basal level of 12% in 5.5 mM glucose to about 35%.  Although uncoupling 
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proteins may also contribute to enhanced proton leak, a genomic study of mouse 
peripheral nerve from embryonic day 17 through adulthood found that transcripts for the 
uncoupling proteins (UCP1-3) were not expressed
46
.  Thus, it is unlikely that 
hyperglycemia also increases UCPs, but additional studies are needed to determine if 
ANT1 directly contributes to the increased proton leak.  
Previous reports have proposed that mitochondrial superoxide production may be 
a unifying biochemical lesion that contributes to increases in polyol synthesis and other 
molecular pathologies of hyperglycemia
4-5
.  However, we were not able to detect a 
significant increase in superoxide production in SC following up to 6 days of 
hyperglycemia and this correlated with an increase in mitochondrial Mn-SOD expression 
and activity.  Vincent and colleagues recently reported a similar resistance of SCs to 
glucose-dependent oxidative stress that correlated with a rapid increase in nuclear levels 
of Nrf2, a critical transcription factor which regulates the expression of antioxidant genes 
such as superoxide dismutase, catalase, and heme oxygenase 1
47
.  Indeed, the basal 
activity of catalase in SCs was about 4-fold greater than the corresponding activity in 
sensory neurons
47
.  It is also interesting to note that increased proton leak can also protect 
against mitochondrial damage induced by reactive oxygen species, such as superoxide
48-
49
.  Together, these results suggest that in neonatal SCs, mitochondria may possess 
multiple pathways to help minimize short-term glucose-induced oxidative stress and that 
hyperglycemia can alter the SC mitochondrial proteome independent of superoxide 
generation.  On the other hand, 24 h of hyperglycemic stress increased superoxide levels 
and overall protein nitration in commercially supplied, cultured adult human SCs
6,50
.  
Unfortunately, the reason for the discrepant results between primary neonatal rat and the 
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adult human SCs is unclear.  One possibility may reside in the maturity or natural history 
of the adult human SCs.  Precedence exists that developmental maturity can affect the 
response of cells to hyperglycemia since 24 h of hyperglycemia induces death of rat 
embryonic sensory neurons after 3 days in culture
24,51
.  However, adult rat sensory 
neurons and embryonic sensory neurons that have been permitted to mature and 
differentiate in culture for 3 weeks are both resistant to glucose-induced apoptosis
52-53
.  
Importantly, it is unlikely that the neonatal cells have lost the SC phenotype and/or the 
ability to respond to hyperglycemic stress since they are competent to myelinate
53
, a 
hallmark of SC function.  Whether the adult human SCs are myelination competent is 
unclear.  Additionally, the myelinated neonatal SCs can respond to hyperglycemic stress 
since the extent of neuregulin-induced demyelination was increased by high glucose 
concentrations
53
.  Thus, primary neonatal and adult SCs may serve as complementary 
models to examine the effect of glucose on the mitochondrial proteome and function in 
the absence or presence of substantial superoxide production, respectively.  
It is important to note that SCs undergo degeneration in diabetic neuropathy
54 
and 
that increased superoxide production, protein nitration, and mitochondrial dysfunction 
contributes to DPN
55
.  At first blush, these results would appear contradictory with our 
findings.  However, it is not surprising that the in vivo increase in superoxide and 
nitrotyrosine levels in SCs after 4 or more weeks of diabetes does not mimic what we 
observed in the primary SC cultures.  Although there are numerous possibilities for this 
difference, one explanation consistent with a recent report is that protective antioxidant 
responses may be overwhelmed with increasing duration of diabetes.  For example, 
diabetic adult sensory neurons mount a transient antioxidant response in response to ex 
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vivo hyperglycemia that is characterized by a brief upregulation of Mn-SOD after one 
day of hyperglycemia followed by a subsequent decline
52
.  Additional studies are needed 
to determine if adult SCs mount a transient antioxidant response during the early onset of 
diabetes that may be eventually overwhelmed with disease duration.  
In conclusion, we have used quantitative proteomics to assess the effect of 
hyperglycemia on the SC proteome.  Hyperglycemia increased the expression of 
numerous mitochondrial proteins but whether this effect is due to an increase in overall 
mitochondrial mass, as previously reported in diabetic heart, remains to be determined.  
Glucose did not increase superoxide production in SCs and this correlated with an 
increase in MnSOD and the extent of proton leak, which may function in reducing 
oxidative stress.  Consistent with a recent report
47
, our data support that primary, neonatal 
rat SCs are rather insensitive to glucose-induced oxidative stress and that the 
mitochondrial proteome can undergo dynamic remodeling in response to hyperglycemia.  
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Chapter 3: C-Terminal Heat Shock Protein 90 Inhibitor 
Decreases Hyperglycemia-induced Oxidative Stress and 
Improves Mitochondrial Bioenergetics in Sensory Neurons  
Zhang, L., Zhao, H., Blagg, B.S.J. and Dobrowsky, R.T. (2012) A C-Terminal Heat Shock 
Protein 90 Inhibitor Decreases Hyperglycemia-induced Oxidative Stress and Improves 
Mitochondrial Bioenergetics in Sensory Neurons. J. Proteome Res. 11, 2581-2593.) 
Abstract  
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes in which 
hyperglycemia-induced mitochondrial dysfunction and enhanced oxidative stress 
contribute to sensory neuron pathology.  KU-32 is a novobiocin-based, C-terminal 
inhibitor of the molecular chaperone, heat shock protein 90 (Hsp90).  KU-32 ameliorates 
multiple sensory deficits associated with the progression of DPN and protects 
unmyelinated sensory neurons from glucose-induced toxicity.  Mechanistically, KU-32 
increased the expression of Hsp70, and this protein was critical for drug efficacy in 
reversing DPN.  However, it remained unclear if KU-32 had a broader effect on 
chaperone induction and if its efficacy was linked to improving mitochondrial 
dysfunction.  Using cultures of hyperglycemically stressed primary sensory neurons, the 
present study investigated whether KU-32 had an effect on the translational induction of 
other chaperones and improved mitochondrial oxidative stress and bioenergetics.  A 
variation of stable isotope labeling with amino acids in cell culture called pulse SILAC 
(pSILAC) was used to unbiasedly assess changes in protein translation.  Hyperglycemia 
decreased the translation of numerous mitochondrial proteins that affect superoxide levels 
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and respiratory activity.  Importantly, this correlated with a decrease in mitochondrial 
oxygen consumption and an increase in superoxide levels.  KU-32 increased the 
translation of Mn superoxide dismutase and several cytosolic and mitochondrial 
chaperones.  Consistent with these changes, KU-32 decreased mitochondrial superoxide 
levels and significantly enhanced respiratory activity.  These data indicate that efficacy of 
modulating molecular chaperones in DPN may be due in part to improved neuronal 
mitochondrial bioenergetics and decreased oxidative stress.  
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3.1 Introduction  
Diabetic peripheral neuropathy (DPN) is a neurodegenerative complication of 
diabetes that develops in 50−60% of diabetic patients
1
.  DPN has proven difficult to 
manage pharmacologically since it does not result from a single biochemical etiology that 
is manifested uniformly for the disease’s duration (10−30 yrs).  Molecular targets that are 
relatively “diabetes specific” (polyol and hexosamine pathways, advanced glycation end 
products) or which are altered in numerous disease states (PKC activation, altered 
neurotrophic support, enhanced oxidative stress) contribute to the progressive 
degeneration of small and large sensory fibers in DPN
2
.  However, current small 
molecule inhibitors of the above pathways/products have yielded few therapeutic agents.  
Clearly, the rational identification of new molecular paradigms that ameliorate DPN and 
offer “druggable” targets affords translational potential for improving the medical 
management of DPN.  
Many neurodegenerative diseases fall into a class of protein-conformational 
disorders since their etiology is linked to the accumulation of specific mis-folded or 
aggregated proteins (for example, β-amyloid and tau in Alzheimer’s disease)
3
.  Though 
the etiology of DPN is not causally linked to the accrual of any one specific mis-folded or 
aggregated protein, hyperglycemia can increase oxidative stress
4
.  The oxidative 
modification of amino acids
5-6
 can impair protein folding
3
, decrease mitochondrial 
function and protein import
2,5,7
 and increase interaction with molecular chaperones
8
. 
Molecular chaperones such as heat shock proteins 90 and 70 (Hsp90, Hsp70) are 
critical for folding nascent proteins.  However, both of these chaperones are components 
of the cellular heat shock response (HSR).  Numerous conditions that promote cell stress 
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lead to the Hsp90-dependent induction of the HSR which, in part, promotes the transient 
up-regulation of Hsp70 to aid the refolding or clearance of aggregated and damaged 
proteins
8
.  Hsp70 upregulation can also prevent neuronal apoptosis
9
 and decrease 
oxidative stress in neurodegenerative disorders
10
.  Importantly, the HSR can be 
pharmacologically activated by inhibiting Hsp90 and we have developed and validated 
KU-32 as a novel, novobiocin-based, C-terminal Hsp90 inhibitor
11-12
 that protects against 
in vitro neuronal cell death
13-14
.  KU-32 also effectively reversed preexisting 
psychosensory and electrophysiologic deficits of DPN in mice and its efficacy required 
Hsp70 since  the drug was ineffective at reversing DPN modeled in Hsp70.1 and Hsp70.3 
double knockout mice
15
.  While these data clearly support that modulating molecular 
chaperones offers a potentially novel approach toward treating sensory neuron 
dysfunction in DPN, additional insight into the mechanism by which KU-32 may 
improve the function of glycemically stressed neurons is needed.  
Increased oxidative stress and mitochondrial dysfunction are strongly implicated 
in the pathogenesis of DPN
5,16
.  Using variations of stable isotope labeling of amino acids 
in culture (SILAC), we have recently shown that numerous mitochondrial proteins are 
downregulated in response to hyperglycemia in cultured primary Schwann cells and 
dorsal root ganglia obtained from diabetic rats
17-18
.  Importantly, decreases in the 
mitochondrial proteome correlated with a decrease in mitochondrial respiratory 
capacity
18
.  However, as the level of all proteins is affected by the balance between their 
rates of synthesis versus degradation, these studies provided no insight into possible 
effects of hyperglycemia on the rate of protein translation.  Indeed, little is known 
regarding the effect of hyperglycemia on rates of protein translation in sensory neurons.  
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In the present study, we took an unbiased approach to address the effect of 
hyperglycemia on protein translation using pulse SILAC (pSILAC)
19
.  Moreover, since 
the mechanism of KU-32 invokes an increase in chaperone translation, we assessed the 
effect of hyperglycemia and KU-32 treatment on translation of mitochondrial proteins in 
sensory neurons.  We identify that hyperglycemia decreases the translation of numerous 
mitochondrial proteins and this correlates with an increase in mitochondrial superoxide 
levels and a decrease in mitochondrial respiratory function.  KU-32 increased the overall 
rate of protein translation in glycemically stressed neurons, including several cytosolic 
and mitochondrial chaperones, components of the mitochondrial respiratory chain and 
Mn superoxide dismutase (MnSOD).  Importantly, these changes correlated with a 
decrease in mitochondrial superoxide levels and increased mitochondrial respiratory 
capacity.  Collectively, these data suggest that KU-32 may improve the sensory deficits 
associated with DPN by enhancing chaperone levels and improving mitochondrial 
function.  
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3.2 Experimental Procedure 
Preparation of Embryonic Dorsal Root Ganglion Sensory Neurons  
Dorsal root ganglion (DRG) neurons were dissected from embryonic day 15−18 
rat pups and the ganglia were collected into L15 medium
20
.  The tissue was dissociated 
with 0.25% trypsin at 37 °C for 30 min, the cells resuspended in DMEM containing 25 
mM glucose, 10% fetal calf serum (FCS, Atlas Biologicals, Fort Collins, CO) and 
triturated with a fire-polished glass pipette.  The cells were counted and plated in the 
center of collagen coated (0.1 mg/mL collagen followed by overnight air drying in a 
laminar flow hood) 35 mm dishes at a density of (2−3) × 10
5 
cells per dish.  The cells 
were cultured in maintenance medium composed of DMEM (4.5 mg/mL glucose, 25 
mM) containing 10% dialyzed FCS, 1× penicillin/streptomycin, 1× gentamicin and 50 
ng/mL NGF (Harlan Biosciences, Indianapolis, IN).  To remove proliferating cells, the 
neurons were treated with 40 μM of fluorodeoxyuridine and 10 μM cytosine β-D-
arabinoside for two days and the drugs withdrawn for 2 days; this cycle was repeated 
two more times.  As the basal glucose concentration in the culture medium was 25 mM, 
hyperglycemia was induced by the addition of 20 mM excess glucose as we and others 
have described previously
15,21-22
.  All animal procedures were performed in accordance 
with protocols approved by the Institutional Animal Care and Use Committee and in 
compliance with standards and regulations for care and use of laboratory rodents set by 
the National Institutes of Health.  
[
3
H]Leucine Pulse  
To assess the global effect of hyperglycemia and KU-32 on protein translation, 
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neurons were seeded in 12 well plates at 1 × 10
5 
cells per well and treated for 5 days in 
the absence or presence of 45 mM glucose.  During the final 24 h of the incubation, the 
cells were treated with DMSO or 1 μM KU-32 and pulsed with 1 μCi/ml L-[2,3,4,5-
3
H]Leucine (American Radiolabeled Chemicals, St. Louis, MO).  The cells were washed 
with ice-cold phosphate-buffered saline (PBS), scraped into 50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 1 mM EDTA, 1% NP40, 1x Complete protease inhibitors (Roche 
Diagnostics, Indianapolis, IN) and an aliquot removed for protein determination.  Equal 
amounts of total protein were precipitated by the addition of ice cold trichloroacetic acid 
to a final concentration of 25% and the precipitate was pelleted by centrifugation.  The 
pellet was washed twice with −20 °C acetone, air-dried and radioactivity quantified by 
scintillation spectrometry.  
pSILAC Labeling  
Lysine (Lys)/Arginine (Arg) deficient DMEM and isotopically enriched (>98%) 
[
2
H4] L-Lys; [
13
C6] L-Arg; [
13
C6,
15
N2] L-Lys and [
13
C6, 
15
N4] L-Arg were purchased from 
Sigma-Isotec (St. Louis, MO).  For each neuron preparation, we performed three different 
sets of experiments to analyze the effect of hyperglycemia and KU-32 on protein 
translation.  The isotopic mixtures and treatments used in the pSILAC
19
 experiments are 
summarized in Table 1.  To assess the effect of hyperglycemia on translation, the neurons 
were cultured in maintenance medium containing 125 mg/L 
12
C-Lys and 84 mg/L 
12
C-
Arg (K0R0) in the absence or presence of 45 mM glucose for 5 days.  For the final 48 h 
of the incubation, control cultures were isotopically pulsed in DMEM supplemented with 
[
2
H4] Lys and [
13
C6] Arg (K4R6) while cells subjected to hyperglycemia were pulsed in 
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culture medium containing [
13
C6,
15
N2] Lys and [
13
C6, 
15
N4] Arg (K8R10).  To assess the 
effect of KU-32 on translation under normoglycemic conditions, the drug was added for 
the final 24 h to neurons pulsed with K8R10; cells pulsed with K4R6 received DMSO.  
When assessing the effect of KU-32 on translation under hyperglycemic conditions, 
neurons were maintained in medium containing 45 mM glucose for 5 days and 1 μM KU-
32 was added for the final 24 h to neurons pulsed with K4R6; DMSO was added to the 
cultures pulsed with K8R10.  KU-32 [N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-
6,6-dimethyl-tetrahydro-2H–pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl) 
acetamide] was synthesized and structural purity (>95%) verified as previously 
described
23
. 
At the end of the incubations, the cells were washed with ice-cold PBS and 
resuspended in 0.5 mL of mitochondrial isolation buffer (MIBA) containing 10 mM Tris-
HCl, pH 7.4, 1 mM EDTA, 0.2 M D-mannitol, 0.05 M sucrose, 0.5 mM sodium 
orthovanadate, 1 mM sodium fluoride and 1× Complete protease inhibitors
24
.  The cells 
were homogenized and the protein concentration of each lysate was measured in 
quadruplicate using the Bradford assay and bovine serum albumin as the standard.  The 
samples were then mixed together in a 1:1 mass ratio and the combined lysate was 
centrifuged at 800× g for 10 min at 4 °C.  The supernatant was recovered, a heavy 
mitochondrial fraction isolated by centrifugation at 8000× g for 5 min at 4 °C and the 
pellet washed twice with ice-cold MIBA buffer.  Three biological replicates were 
performed for the MS analysis using neurons obtained from separate litters of embryonic 
rat pups.  Three additional biologic replicates using neurons obtained from separate litters 
were performed to validate some of the MS data using immunoblot analysis: monoclonal 
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antibodies included Hsp70, mitochondrial Hsp70 and Hsc70 (Stressgen/Enzo Life 
Sciences, Farmingdale, NY); MnSOD (Upstate Biotechnology/Millipore, Billerica, MA) 
and β-actin (MP Biomedicals, Solon, OH).  Hsp60 and Hsp70 protein 12A polyclonal 
and secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).  
Mass Spectrometry and Protein Identification  
Proteins were identified following one-dimensional SDS-PAGE coupled to RP-
HPLC linear quadrupole ion trap Fourier transform ion cyclotron resonance tandem mass 
spectrometry (GeLC-LTQ-FT MS/MS)
25
.  About 50 μg of protein was fractionated by 
SDS-PAGE, the proteins were visualized by staining the gel and the lanes were cut into 
10−12 × 0.5 cm sections for in-gel tryptic digestion.  
Tryptic digestion of the proteins was performed as described previously
17-18
.  The 
peptides were separated on a 0.30 × 150 mm, Pepmap C18 microcapillary reverse-phase 
column at a flow rate of 5−10 μL/min with a linear gradient from 5 to 65% acetonitrile in 
0.06% aqueous formic acid (v/v) over 65 min.  The eluate was introduced into the LTQ-
FT tandem mass spectrometer (ThermoFinnigan, Waltham, MA) and mass spectra were 
acquired in the positive ion mode.  All experiments were performed in data-dependent 
mode using dynamic exclusion with survey MS spectra (m/z 300−2000) acquired in the 
FT-ICR cell with resolution R = 50000 at m/z 400 and accumulation to a target value of 5 
× 10
5 
charges, or a maximum ion accumulation time of 2000 ms.  The five most intense 
ions were isolated and fragmented with a target value of 2 × 10
3 
accumulated ions and an 
ion selection threshold of 3000 counts.  Dynamic exclusion duration was typically 180 s 
with early expiration if ion intensity fell below a S/N threshold of 2.  The ESI source was 
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operated with a spray voltage of 2.8 kV, a tube lens offset of 130 V and a capillary 
temperature of 200 °C.  All other source parameters were optimized for maximum 
sensitivity of a synthetic YGGFL peptide ion at m/z 556.27.  
Protein Identification and Quantification  
Peak lists were acquired from the Xcalibur .raw files using MaxQuant v1.1.1.36
26
.  
Protein identification utilized the integrated Andromeda search engine
27
 queried against 
the rat IPI database (v3.80, 39,473 entries) that was concatenated with forward plus 
reverse sequences and supplemented with common contaminants.  Search parameters 
specified a MS tolerance of 20 ppm, a fragment tolerance of 0.5 Da, up to 2 missed 
cleavages, 3 labeled amino acids per peptide and carboxyamidomethylated cysteine as a 
fixed modification.  Variable modifications were set to consider methionine oxidation 
and protein N-terminal acetylation.  It is not necessary to specify the isotopic labels as 
variable modifications when using the MaxQuant software
28
 but the multiplicity was set 
to three to consider the K4R6 and K8R10 isotope combinations.  
The experimental design template of MaxQuant was constructed such that the 
Xcalibur .raw MS files were grouped together for the three biological replicates 
(including any technical duplicates) for each treatment group shown in Table 1.  For 
identification, peptides were required to be at least 6 amino acids in length and protein 
identification required at least one razor plus unique peptide.  A protein was only 
included in the final analysis if it was identified by at least one peptide in two treatment 
groups.  The false discovery rates were set to 1% at the peptide and protein levels. 
Posterior error probabilities (PEP, false hit probability given the peptide score and 
length)
26
 ranged from 0 to 0.54 (95% of proteins had a PEP < 0.05), and after mass 
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recalibration, the average absolute mass deviation was 1.62 ppm.  Annotated MS/MS 
spectra were derived from the .raw files using the Viewer feature of MaxQuant.  
For protein quantitation, we activated the requant feature and specified a single 
ratio count of unmodified and variably modified peptides for quantitation.  For all the 
quantified peptides of a given protein, MaxQuant reports the median of these expression 
ratios and the non-normalized ratios are reported in Supplemental Table 2-1 (Appendix).  
Gene ontology (GO) annotations were obtained using the Uniprot identifier and the 
Perseus component of the MaxQuant software suite.  Enrichment analyses were 
performed using the Database for Visualization and Integrated Discovery (DAVID)
29
 and 
the Biological Networks Gene Ontology (BinGO)
30
 plug-in of Cytoscape
31
. 
Superoxide Assessment  
Superoxide levels were measured by following the oxidation of dihydroethidine 
(Invitrogen-Molecular Probes, Carlsbad, CA) to ethidium
32
.  Neurons were seeded at 1 × 
10
4 
cells per well in black 96-well plates, treated overnight with 1 μM KU-32 then for 6h 
with 25 mM or 45 mM glucose.  After 6h, the cells were subsequently treated with 15 
μM dihydroethidine for 15 min at 37 °C.  After washing with PBS, the ratio of ethidium 
(excitation 530 nm, emission 590 nm) to dihydroethidine (excitation 485 nm, emission 
530 nm) was determined using a fluorescence spectrometer.  
To directly assess mitochondrial superoxide production, the cells were treated as 
above and washed twice with phenol free Neurobasal medium.  MitoTracker Green (80 
nM) and 0.4 μM MitoSOX Red were added to each well and incubated for 15 min
33
.  The 
cells were washed twice with fresh Neurobasal medium prior to imaging on an Olympus 
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3I Spinning Disk confocal microscope using excitation/emission wavelengths of 575/624 
nm (MitoSox Red) and 494/531 nm (MitoTracker Green)
34
.  As a positive control, some 
cells were treated with 1.8 μg/mL antimycin A for 25 min.  Fluorescence intensity of the 
red and green signals of at least 200 cells per treatment was obtained using CellProfiler 
and CellProfiler Analyst image analysis software.  
Mitochondrial Respiration  
O2 consumption rate (OCR) was assessed using intact DRG sensory neurons and 
a XF96 Extracellular Flux Analyzer (Seahorse Biosciences, North Billerica, MA).  
Extracellular flux analysis is a noninvasive assay which uses two calibrated optical 
sensors to directly measure OCR in real-time in neurons that remain attached to the 
culture plate
35
.  Primary embryonic sensory neurons were seeded in the 96 well plates at 
1.5 × 10
4 
cells per well and treated for 5 days in 25 or 45 mM glucose.  Cells were treated 
with 1 μM KU-32 or DMSO for the final 24 h of the incubation and the cells were placed 
in fresh bicarbonate-free DMEM containing 5 mM glucose and 1 mM pyruvate.  Baseline 
OCR was assessed in the XF96 analyzer using 4 measurement loops consisting of a 2 min 
mix cycle and a 5 min measurement cycle.  Respiratory chain inhibitors were then 
sequentially injected into the wells and ATP-coupled oxygen consumption was calculated 
as the fraction of the basal OCR sensitive to 1 μg/mL oligomycin, an ATP synthase 
inhibitor.  The maximal uncoupled respiration rate was determined by depolarizing the 
mitochondrial membrane potential with 1 μM FCCP (carbonylcyanide-4-(trifluorome-
thoxy)-phenylhydrazone).  The cell seeding density and inhibitor concentrations were 
optimized in preliminary experiments.  After the respiratory measures, the cells were 
harvested and experimental rate values were normalized to protein content of each well. 
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Maximal respiratory capacity, spare respiratory capacity and respiratory state apparent 
(Stateapp) were determined from the rate data as described
36-37
. 
Statistical Analyses  
All statistical differences between treatments were determined using ProStat 
(v4.83). Data were analyzed using either a one-way ANOVA and Tukey’s post hoc test 
or a Kruskal−Wallis test and Dunn’s posthoc analysis.  
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3.3 Results  
We have shown previously that 2−3 week old cultures of embryonic sensory 
neurons can serve as a cell model to examine mechanisms of hyperglycemic stress.  After 
two weeks in culture, embryonic sensory neurons were subjected to five days of 
hyperglycemia and the global effect on protein translation was measured by pulsing the 
cells with [
3
H] Leu for the final 24 h.  Hyperglycemically stressed neurons showed a 22% 
decrease in [
3
H]Leu incorporation and treating the cells with 1 μM KU-32 for 24 h prior 
to the Leu pulse significantly increased overall translation (Figure 3-1).  These results 
suggest that modulating chaperones may broadly increase protein translation.  
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Figure 3-1. Hyperglycemia decreases the incorporation of [3H]Leucine into protein.  
Primary sensory neurons were cultured for 5 days in medium with 25 mM or 45 mM glucose and 
treated with DMSO or 1 μM KU-32 for the final 24 h.  Coincident with the addition of KU-32, 
the cells were pulsed with 1 μCi/ml [
3
H]Leu and the incorporation of of [
3
H]Leu into total protein 
was determined as described in Experimental Procedures.  The total dpm/μg protein was 
determined and the results are expressed as the percent of control. The data are the mean ± SEM 
from three experiments. *, p < 0.05 compared to control; #, p < 0.05 compared to glucose minus 
KU-32.  
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To identify specific proteins whose translation was differentially effected by 
hyperglycemia and KU-32, we utilized the pSILAC strategy that has been previously 
described
19
 and is outlined in Figure 3-2.  To assess the effect of KU-32 on protein 
translation in hyperglycemically stressed sensory neurons, the cells were incubated in 
K0R0 culture medium containing 45 mM glucose.  After 3 days, the K0R0 cultures were 
divided such that one set of cells was placed in hyperglycemic culture medium containing 
medium-heavy forms of Lys and Arg (K4R6).  The cells were pulsed with K4R6 for 48 h 
and treated with 1 μM KU-32 for the final 24 h of the incubation. The remaining K0R0 
cells were placed in hyperglycemic culture medium containing heavy isotope forms of 
Lys and Arg (K8R10) and treated with DMSO for the final 24 h of the incubation.  
During the isotopic pulse, all newly synthesized proteins can only incorporate the K4R6 
or K8R10 forms of Lys and Arg.  Total cell lysates were prepared from the two treatment 
groups and mixed in a 1:1 mass ratio prior to isolation of subcellular fractions.  Following 
mass spectrometric analysis, the abundance ratio of a K4/K8 or R6/R10 peptide reflects 
the difference in translation of the associated protein due to KU-32 treatment under 
hyperglycemic conditions (Table 3-1).  Since all the K0R0 peptides associated with a 
given protein are present prior to the pulse, they can be ignored as they do not represent 
newly translated protein
19
. 
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Table 3-1. Isotopic Combinations for pSILAC Experiments  
 
 
 
Figure 3-2. Experimental strategy for pSILAC analyses.  Primary neurons were 
cultured in medium containing 45 mM glucose and light forms of Lys and Arg (K0R0) for 3 days.  
The K0R0 cultures were divided in half and one set of cells was placed in hyperglycemic culture 
solution containing medium-heavy forms of Lys and Arg (K4R6).  The cells were pulsed with 
Label Combination Treatment Ratio 
Analyzed 
Interpretation 
K4R6 (M) : K8R10 (H) 25 mM glucose : 45 mM glucose H/M Effect of 5 day hyperglycemia on translation 
 
K4R6 (M) : K8R10 (H) 25 mM glucose : 25 mM glucose + KU-
32 
H/M Effect of 24 h KU-32 treatment on translation 
in basal glucose 
K4R6 (M) : K8R10 (H) 45 mM glucose + KU-32 : 45 mM 
glucose 
M/H Effect of 24 h KU-32 treatment on translation 
under hyperglycemic conditions 
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K4R6 for 48 h and treated with 1 μM KU-32 for the final 24 h.  The remaining K0R0 cells were 
placed in hyperglycemic culture medium containing heavy isotope forms of Lys and Arg 
(K8R10) and treated with DMSO for the final 24 h of the incubation.  Total cell lysates were 
prepared and mixed in a 1:1 mass ratio, a heavy mitochondrial fraction was isolated, and the 
proteins were separated by SDS-PAGE prior to tryptic digestion and MS/MS analysis.  
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MaxQuant identified 743 proteins, of which 577 were identified by at least 2 
peptides and 280 were quantified (Supplementary Table 2-2, Appendix).  Approximately 
one-third of the 280 quantified proteins were present in all of the treatments (Figure 3-
3A) and of the 156 proteins annotated as mitochondrial, 79 were quantified.  Though the 
log 2 distributions of the protein expression ratios for each treatment were relatively 
unimodal, they were asymmetric and consistent with hyperglycemia decreasing protein 
translation and KU-32 treatment of hyperglycemically stressed cells increasing 
translation (Figure 3-3B).  To determine what biological processes may be over-
represented following KU-32 treatment, proteins showing at least a 1.5 fold increase were 
submitted to enrichment analysis using DAVID and the BinGO plug-in of Cytoscape.  
Both analyses supported that protein folding and response to reactive oxygen species 
were among the enriched biological processes identified (both ∼11-fold enrichment).  
KU-32 Effects Expression of Multiple Molecular Chaperones  
The effect of hyperglycemia in absence and presence of KU-32 treatment on the 
expression of chaperones (green) and proteins with a mitochondrial annotation (red) is 
shown in Figure 3-3C. We have shown previously that KU-32 induces cytosolic Hsp70
13
 
and rather unexpectedly, we did not detect this Hsp70 paralog in any treatment group.  
This may be due to its relatively low abundance in the neurons compared to the 
constitutive form of Hsp70 (Hsc70), which is highly abundant and has a similar 
molecular weight (Figure 3-3D).  Although an enriched mitochondrial preparation was 
used in the analysis, cytosolic Hsc70 was among the top ten identifications based on total 
number of peptides identified, but was not significantly modified in any treatment.  
However, immunoblot analysis of whole cell lysates revealed that KU-32 significantly 
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increased Hsp70 expression in hyperglycemically stressed neurons (Figure 3-3D).  
A surprising finding of the pSILAC analysis was that KU-32 also increased 
mitochondrial chaperones under hyperglycemic conditions.  Hsp60 is necessary to ensure 
the proper folding of proteins imported into the mitochondrial matrix
38
 and compared to 
hyperglycemia alone, KU-32 promoted a median increase in translation of 3.7-fold 
(Figure 3-3C).  An example of a pSILAC isotopic triplet of mtHsp60 is shown in Figure 
3-4A.  As expected, the unlabeled AAVEEGIVIGGGCAII(R0) peptide is of substantially 
greater intensity than the newly translated labeled peptides (note 5× scale amplification 
for the K4R6 and K8R10 peaks) since it existed prior to the pulse, and its intensity has 
additive contributions from sample mixing.  When comparing the R6 and R10 forms of 
the peptide as indicative of newly translated protein, KU-32 treatment (R6 peptide at m/z 
845.97) clearly enhanced the translation of Hsp60 relative to hyperglycemia alone (note 
that the mass differences between the peaks are one-half the expected amu shift since the 
peptides are doubly charged).  In contrast, Hsp10 is a mitochondrial chaperone that was 
identified but not quantified in any treatment, suggesting that it had a lower rate of 
translation.  
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Figure 3-3. Distribution of translationally induced proteins.  (A) Venn diagram of 
quantified proteins in each group.  Numbers in parentheses are total number of quantified proteins 
per treatment.  Percent of unique and overlapping proteins are shown within the colored sections 
of the diagram.  (B) Non-normalized protein expression ratios provided by MaxQuant were log 2 
transformed, binned into 0.5 units and the total proteins per bin counted.  (C) Expression ratios of 
all quantified chaperones (green) and mitochondrial proteins (red) detected in both the high 
glucose and high glucose + KU-32 treatments were plotted against each other.  (D) 
Representative immunoblot and quantitation of Hsp70 levels from three separate neuronal 
cultures. *, p < 0.05 compared to control; #, p < 0.05 compared to glucose minus KU-32.  
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Mortalin/Grp75/stress-70 protein is a mitochondrial Hsp70 (mtHsp70) family 
member that is a component of the presequence translocase-associated motor complex
39
 
and its translation was modestly decreased by hyperglycemia.  Similar to Hsp60, the 
identification of mtHsp70 was by numerous peptides in each treatment.  Figure 3-4B 
shows the MS/MS spectra of a peptide that was identified by seven sequential y-and b-
ions that were increased about 1.8-fold by KU-32 in cells subjected to hyperglycemic 
stress (Figure 3-4C).  Importantly, immunoblot analysis from 3 separate neuronal cultures 
further verified this finding (Figure 3-4C).  In contrast to Hsp60, mtHsp70 is not induced 
as part of the classic heat shock response, however, it is upregulated in response to other 
forms of cell stress and its overexpression can improve mitochondrial function during 
focal ischemia
40
.  Additionally, about 99% of mitochondrial proteins are nuclear encoded 
and require translocation and import into the organelle
39
.  Although little is known on the 
effect of diabetes on mitochondrial protein import in sensory neurons, diabetes decreased 
the rate of protein import into interfibrillar, but not subsarcolemmal cardiac 
mitochondria
7
.  Since mtHsp70 and Hsp60 are respectively involved in the import and 
folding of proteins into the mitochondrial matrix
38
, these data suggest that KU-32 may 
affect mitochondrial function by facilitating protein import and maturation.  
KU-32 also promoted a 4.9-fold increase in the expression of another Hsp70 
paralog, Hsp70 protein 12A (Hsp70 p12A), and this was verified by immunoblot analysis 
of separate neuronal cultures (Figure 3-4D).  Hsp70 p12A is an atypical member of the 
Hsp70 family and despite the fact that HSPA12 genes evolved early in the evolution of 
vertebrates
41
, the protein’s localization and function remain poorly characterized.  Recent 
reports have provided descriptions that Hsp70 p12A expression is decreased in prefrontal 
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cortex of schizophrenic brain
42
 and increased in artherosclerotic lesions
43
, but no 
functional properties were ascribed to these observations.  Since Hsp70 p12A contains 
atypical ATPase and substrate binding domains
41
, it may function as a co-chaperone.  
Neither Hsp90α nor Hsp90β were significantly altered by KU-32 in the 
hyperglycemic neurons.  Curiously, KU-32 induced a 1.5-fold increase in calnexin 
translation, which is a chaperone involved in protein quality control in the endoplasmic 
reticulum (ER).  However, other ER chaperones such as Grp78 and Grp94 were readily 
identified by numerous peptides but not quantified, suggesting that they were not 
undergoing substantial changes in translation.  Together, these data support that in 
hyperglycemically stressed neurons, inhibiting the C-terminus of Hsp90 is sufficient to 
increase several Hsp70 family members and other mitochondrial chaperones.  
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Figure 3-4. KU-32 induces the translation of Hsp60 and Hsp70 family members in 
hyperglycemic neurons.  Primary neurons were incubated in medium containing 45 mM glucose 
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for 3 days and pulsed with either K4R6 or K8R10 Lys/Arg for an additional 48 h.  The cultures 
were treated with 1 μM KU-32 (K4R6) or DMSO (K8R10) for the final 24 h of the incubation.  
Cell lysates were prepared, mixed in a 1:1 ratio and the samples processed for MS/MS analysis.  
(A) Representative MS scan showing an increase in Hsp60 in hyperglycemic neurons treated with 
KU-32 (R6 peptide) compared to glucose only (R10 peptide).  Note the 5× scale amplification to 
demonstrate the increase in the R6 peptide compared to the R10 peptide.  (B) MS/MS spectrum 
of the SQVFSTAADGQTQVEIK peptide of mtHsp70.  The majority of the unannotated peaks 
arise from the loss of water and ammonia ion but their labeling was omitted for clarity.  The 
asterisk indicates a peak that was unassigned.  (C) Representative MS scan showing an increase 
in mtHsp70 in hyperglycemic neurons treated with KU-32 (K4 peptide) compared to glucose only 
(K8 peptide); 5× scale amplification as discussed above.  A representative immunoblot and 
quantitation (n = 3) of the effect of hyperglycemia and KU-32 on mtHsp70 expression is shown 
to the right of the spectrum.  (D) Representative MS scan showing an increase in Hsp70 p12A in 
hyperglycemic neurons treated with KU-32 (K4 peptide) compared to glucose only (K8 peptide); 
5× scale amplification as discussed above.  A representative immunoblot and quantitation (n = 3) 
of the effect of hyperglycemia and KU-32 on Hsp70 p12A expression is shown to the right of the 
spectrum. *, p < 0.05 compared to control; #, p < 0.05 compared to glucose minus KU-32.  
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KU-32 Increased MnSOD Translation and Decreased Glucose-induced 
Superoxide Production  
An established hallmark of mitochondrial dysfunction in DPN is the induction of 
oxidative stress, due in part to an increase in mitochondrial superoxide production
4
.  
Consistent with these data and our previous results
18
, translation of MnSOD in 
hyperglycemically stressed neurons was about 50% less than that measured in control 
neurons (3 peptides quantified) and KU-32 promoted a 2.3 fold increase in the translation 
of MnSOD (Figure 3-5A) in the hyperglycemically stressed cells.  Although only 
quantified by 2 peptides, the identification of this doubly charged peptide was 
substantiated by a sequential series of 10 b-ions and 11 y-ions (Figure 3-5B).  Moreover, 
immunoblot analysis of separate neuronal cultures verified that hyperglycemia decreased 
MnSOD and that KU-32 treatment significantly increased its expression (Figure 3-5A).  
To determine if the increase in MnSOD by KU-32 corresponded to a decrease in 
superoxide production, the ratio of ethidium/dihydroethidium was used as a nonorganelle 
selective measure of superoxide.  Neurons were pretreated with vehicle or KU-32 and 
exposed to 45 mM glucose for 6 h to acutely increase superoxide levels
22
.  
Hyperglycemia increased superoxide levels and KU-32 significantly blocked this effect 
(Figure 3-5C).  To determine if KU-32 prevented superoxide production within 
mitochondria in neurons subjected to the more chronic hyperglycemic stress that was 
used in the proteomic analyses, we used MitoSox red and the mitochondrial marker, 
MitoTracker Green.  Five days of hyperglycemia increased mitochondrial superoxide 
levels and treating the cells with KU-32 for the final 24 h significantly decreased this 
response (Figure 3-5D & E).  As a positive control, some neurons were treated with 
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antimycin A prior to the addition of the dyes.  These data support that modulating the 
activity of Hsp90 with KU-32 is sufficient to increase MnSOD and decrease glucose-
induced mitochondrial oxidative stress.   
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Figure 3-5. KU-32 induces the translation of MnSOD and decreases mitochondrial 
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superoxide in hyperglycemic neurons.  Primary neurons were incubated in medium containing 
45 mM glucose for 3 days and pulsed with either K4R6 or K8R10 Lys/Arg for an additional 48 h.  
The cultures were treated with 1 μM KU-32 (K4R6) or DMSO (K8R10) for the final 24 h of the 
incubation.  Cell lysates were prepared, mixed in a 1:1 ratio and the samples processed for 
MS/MS analysis.  (A) Representative MS scan showing an increase in MnSOD in hyperglycemic 
neurons treated with KU-32 (R6) compared to glucose only (R10).  Note the 5× scale 
amplification to demonstrate the increase in the R6 relative to R10 peptide.  A representative 
immunoblot and quantitation (n = 3) of the effect of hyperglycemia and KU-32 on MnSOD 
expression is shown to the right of the spectrum.  (B) MS/MS spectrum of the 
AIWNVINWENVSQR peptide.  The majority of the unannotated peaks arise from the loss of 
water and ammonia ion but their labeling were omitted for clarity. The asterisk indicates a peak 
that was unassigned.  (C) Effect of KU-32 on decreasing glucose-induced superoxide production 
as measured using the ratio of ethidium/dihyroethidine.  Results are expressed as a fold control 
and are the mean ± SEM from three separate cultures. Gluc; 45 mM glucose.  (D) Representative 
images showing that KU-32 decreased glucose-induced mitochondrial superoxide production as 
visualized using MitoSox Red.  Neurons were costained with Mitotracker Green to localize 
mitochondria.  Gray panels show raw gray scale images that were exported prior to being 
colorized in Image J. Cells treated with antimycin A (Ant) served as a positive control for 
superoxide generation.  (E) Quantitative image analysis from three separate neuron cultures. *, p 
< 0.05 compared to control; #, p < 0.05 compared glucose minus KU-32.  
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Increased Translation of Mitochondrial Chaperones and MnSOD by KU-32 
Correlates with an Improved Bioenergetic Profile  
Hyperglycemia-induced oxidative stress renders mitochondrial proteins more 
susceptible to oxidative damage.  Relative to their rate of production, a slower rate of 
repair by mitochondrial chaperones favors accumulation of oxidatively damaged proteins 
in the organelle
44
.  Thus, the ability of KU-32 to increase mitochondrial chaperones and 
decrease oxidative stress suggests that the bioenergetic profile of the organelle may also 
be enhanced.  To this end, we used a XF96 Extracellular Flux Analyzer to assess the 
effect of hyperglycemia and KU-32 treatment on oxygen consumption rat (OCR).  The 
XF96 analyzer measures OCR in real time using intact cells and results in Figure 3-6A 
show a typical mitochondrial function experiment from ∼5000 sensory neurons per well 
(n =4) respiring in DMEM containing 5.5 mM glucose.  The first four rates represent 
basal OCR (light blue shading) and each rate measure was normalized to the total amount 
of protein per well and expressed as a percent of the final basal OCR (rate 4).  Measuring 
OCR in intact cells in the absence and presence of respiratory chain poisons is the single 
most useful test to stringently assess mitochondrial dysfunction
36
.  Oligomycin is an ATP 
synthase inhibitor and its injection decreases the basal OCR.  The magnitude of this 
decrease is indicative of the percent of the basal OCR that is coupled to ATP synthesis 
(dark blue shading) and the residual OCR is due to proton leak (uncoupled respiration).  
FCCP is a protonophore whose addition provides a measure of maximal respiratory 
capacity (MRC, red shading).  MRC assesses the functional integrity of the respiratory 
chain since electron transfer is no longer rate limited by the proton gradient across the 
inner mitochondrial membrane
36
.  Nicholls has defined spare respiratory capacity (SRC) 
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as the arithmetic difference between MRC and the basal OCR (pink shading)
45
.  SRC 
provides a functional indication of how close to its bioenergetic limit a cell is respiring
36
.  
A loss of SRC, especially in neurons that have variable ATP demands, limits their ability 
to match energetic needs to environmental demands and renders the cells more 
susceptible to secondary stressors
46-47
.  Thus, treatment-induced differences in MRC and 
SRC are indicative of mitochondrial dysfunction affecting the bioenergetic limits and 
reserve capacity of the neurons.  Although not measured in the current experiment, the 
green shading is representative of non-mitochondrial OCR values obtained the presence 
of rotenone and antimycin A to inhibit complexes I and III, respectively.  
Neurons were incubated in medium containing 25 or 45 mM glucose for 5 days 
and treated with KU-32 for the final 24 h.  To assess respiration under a standard glucose 
concentration, the cells were placed in serum-free DMEM containing 5.0 mM glucose 
and 1 mM pyruvate at 37 °C for 1 h prior to measuring OCR.  After measuring basal 
OCR, the cells were exposed to oligomycin and no significant differences were observed 
in the magnitude of ATP-coupled OCR and proton leak (Figure 3-6B).  In contrast, 
though FCCP stimulated MRC above basal OCR in all treatments, neurons exposed to 
hyperglycemic stress exhibited a significantly blunted MRC relative to control cells 
(Figure 3-6B).  Similarly, SRC was also significantly decreased in the glycemically 
stressed cells compared to control (Figure 3-6C, solid bars).  
In cells maintained in 25 mM glucose and treated with KU-32, the average MRC 
and SRC was slightly decreased but this was not significantly different from control.  
Consistent with the efficacy of KU-32 in decreasing mitochondrial superoxide levels, 
glycemically stressed cells treated with the drug showed a significant improvement in 
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both MRC (Figure 3-6B) and SRC (Figure 3-6C, solid bars) compared to the neurons 
incubated in high glucose alone.  The blunted MRC and SRC apparent in the 
hyperglycemically stressed cells supports that they are energetically stressed and that 
mitochondrial workload is increased.  
The respiratory state apparent (Stateapp) provides a quantitative indication of 
mitochondrial workload and can be estimated from these data
47
.  As mitochondrial 
workload decreases, Stateapp approaches 4, a metabolic indicator that minimal ATP-
coupled respiration is needed and OCR is primarily uncoupled
47
.  On the other hand, high 
ATP demand requires state 3.0 respiration (comparable to that induced by FCCP, Figure 
3-6B).  The Stateapp values were 3.5 ± 0.5 and 3.5 ± 0.3 in neurons treated with vehicle or 
KU-32, respectively, indicating the basal mitochondrial workload required to meet ATP 
needs.  In contrast, hyperglycemia promoted a significant decrease in Stateapp (3.3 ± 0.3, 
Figure 3-6C, striped bars), suggesting that ATP demand is depleting reserve capacity and 
that the organelles are approaching bioenergetic failure
37
.  Importantly, KU-32 treatment 
significantly improved this decline.  The ability of KU-32 to increase MRC, SRC and 
Stateapp supports that the cells have recovered significant respiratory capacity that 
correlates with the induction of mitochondrial chaperones and a decrease in superoxide 
production.  Although numerous factors contribute to OCR
37
, hyperglycemia-induced 
damage to respiratory chain proteins may decrease the efficiency of electron transport to 
affect SRC and increase mitochondrial workload.  
 
  
 
 
132 
 
Figure 3-6. Hyperglycemia decreased mitochondrial bioenergetics which was 
reversed by KU-32 treatment.  (A) Example of a mitochondrial function experiment in the 
XF96 extracellular flux analyzer. Basal OCR (light blue) is given by the first four rate measures.  
The addition of 1 μg/mL oligomycin inhibits ATP synthase and the decrease in OCR gives a 
measure of ATP-coupled respiration (dark blue).  Residual OCR in the presence of oligomycin 
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provides a measure of proton leak (orange).  The addition of 1 μM FCCP dissipates the proton 
gradient across the inner mitochondrial membrane and assesses maximal respiratory capacity 
(MRC, red).  Spare respiratory capacity (SRC, pink) is assessed as the difference between MRC 
and the basal OCR.  The green shading represents the estimated contribution of nonmitochondrial 
respiration to basal OCR but was not directly measured in the experiment shown.  (B) Primary 
neurons were seeded into a 96 well plate and incubated in medium containing 25 or 45 mM 
glucose for 5 days and treated with 1 μM KU-32 or DMSO for the final 24 h.  The cells were 
placed in medium containing 5 mM glucose and 1 mM pyruvate prior to the respiratory measures.  
Results shown are the mean ± SEM from 5 to 8 wells per treatment from one experiment repeated 
three times.  Arrows indicate the injection of oligomycin and FCCP.  Hyperglycemia induced a 
significant decrease in MRC relative to control neurons (*, p < 0.05) and KU-32 treatment 
significantly increased MRC compared to cells treated with high glucose only (#, p < 0.001).  (C) 
Hyperglycemia significantly decreased SRC (*, p < 0.05, left axis and solid bars) and Stateapp (*, 
p < 0.01, right axis and striped bars) compared to control cells.  Both SRC (
# 
, p < 0.001) and 
Stateapp (
# 
, p < 0.05) were significantly improved by KU-32 treatment compared to cells treated 
with high glucose alone.  
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3.4 Discussion 
Our previous work on novobiocin-based C-terminal Hsp90 inhibitors has 
demonstrated that they induce Hsp70 and protect cortical and sensory neurons from 
toxicity induced by β-amyloid peptides and hyperglycemia, respectively
13,15
.  Although 
the neuroprotective efficacy of KU-32 in reversing DPN required the presence of Hsp70, 
the current study sought to unbiasedly identify whether KU-32 promoted the translation 
of other proteins that may aid sensory neurons in tolerating glucotoxic stress
48
.  Using 
pSILAC, we identify that mitochondrial chaperones and MnSOD are also increased by 
KU-32 treatment of hyperglycemically stressed cells.  Consistent with the induction of 
MnSOD, KU-32 decreased mitochondrial superoxide levels in neurons subjected to 5 
days of hyperglycemia.  Similarly, hyperglycemia decreased various measures of 
mitochondrial respiratory capacity and treating the neurons with KU-32 significantly 
improved both maximum and spare respiratory capacity.  
Previous investigators have shown that embryonic sensory neurons cultured in 
vitro for 3 days are susceptible to glucose-induced apoptosis
49-50
.  However, 2−3 week 
old cultures of embryonic sensory neurons are resistant to glucose-induced cell death
11,17
, 
similar to adult sensory neurons
51
.  Although the more differentiated embryonic neurons 
can serve as a cell model to examine mechanisms of hyperglycemic stress unrelated to 
apoptosis, their response to hyperglycemia does not necessarily mimic that observed in 
adult neurons.  For example, hyperglycemia induced a robust increase in superoxide in 
adult sensory neurons isolated from chronically diabetic mice but not from neurons 
obtained from control animals
18,52
.  Thus, obtaining sensory neurons from adult diabetic 
animals that have received drug treatment will also be a beneficial approach toward 
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dissecting the mechanism of drug efficacy on improving mitochondrial function.  
Although correlative, since mitochondrial function is clearly compromised in the 
improved expression of mitochondrial chaperones and enhanced respiratory capacity may 
at least partially underlie the efficacy of KU-32 in reversing sensory hypoalgesia in 
diabetic mice
18,52-53
.  We would like to emphasize that our approach in using the 
differentiated embryonic neurons has no implications on the role or relevance of glucose-
induced apoptosis to DPN.  The neuroprotective properties of KU-32 in ameliorating 
DPN are unlikely to center on preventing sensory neuron death since apoptosis has not 
been demonstrated as a key feature in the development of DPN
54-56
. 
It is important to note that Hsp70 is a necessary component of drug efficacy since 
gene deletion of inducible forms of Hsp70 ablated the ability of KU-32 therapy to reverse 
several indices of experimental DPN
11
.  However, this does not rule out that the induction 
of mitochondrial chaperones and MnSOD are not a critical aspect of the effect of KU-32 
on improving mitochondrial function, and by extension, DPN.  Emerging data supports 
that diabetes increases oxidative stress and mitochondrial fission/fusion in sensory 
neurons
57-59
.  Decreasing oxidative stress and maintaining the fidelity of protein import to 
support this turnover would be essential to maximizing the bioenergetic capacity of the 
organelle.  As both Hsp70 and mtHsp70 aid mitochondrial protein import via separate 
import pathways
39
, we hypothesize that these proteins may enhance mitochondrial 
bioenergetics by facilitating the import of respiratory and antioxidant proteins; MnSOD is 
likely to be imported into the mitochondrial matrix via mtHsp70.  To this end, it will be 
critical to define whether the necessity of Hsp70 induction for drug efficacy is related to 
improved mitochondrial function and/or protein import.  Similarly, the 
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sufficiency/necessity of mtHsp70 and MnSOD induction by KU-32 to improving 
mitochondrial function in response to hyperglycemic stress remains to be determined.  
In conclusion, the salient findings of this study provide proof-of-principle that a 
novel C-terminal Hsp90 inhibitor can decrease mitochondrial superoxide levels and 
improve organellar bioenergetics in hyperglycemically stressed neurons.  These 
functional improvements correlated with the translational induction of MnSOD and 
mitochondrial chaperones by KU-32.  Thus, the reported efficacy of KU-32 therapy in 
ameliorating sensory hypoalgesia in DPN may relate to improved mitochondrial function.  
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Chapter 4: Synthesis and Evaluation of Novologues as C-
Terminal Hsp90 Inhibitors with Cytoprotective Activity 
against Sensory Neuron Glucotoxicity 
(Kusuma, B.R., Zhang,
 
L., Sundstrom, T., Peterson, L.B., Dobrowsky, R.T. and Blagg, B.S.J. 
(2012) Synthesis and Evaluation of Novologues as C-Terminal Hsp90 Inhibitors with 
Cytoprotective Activity against Sensory Neuron Glucotoxicity. J. Med. Chem. 55, 5797-5812) 
Abstract  
KU-32 is a first-generation novologue (a novobiocin-based, C-terminal, heat shock 
protein 90 (Hsp90) inhibitor), that decreases glucose-induced death of primary sensory 
neurons and reverses numerous clinical indices of diabetic peripheral neuropathy in mice. 
The current study sought to exploit the C-terminal binding site of Hsp90 to determine 
whether the optimization of hydrogen bonding and hydrophobic interactions of second 
generation novologues could enhance neuroprotective activity. Using a series of 
substituted phenylboronic acids to replace the coumarin lactone of KU-32, we identified 
electronegative atoms placed at the meta-position of the B-ring exhibit improved 
cytoprotective activity, which is believed to result from favorable interactions with 
Lys539 in the Hsp90 C-terminal binding pocket. Consistent with these results, a meta-3-
fluorophenyl substituted novologue (11b) exhibited a 14-fold lower ED50 compared to 
KU-32 for protection against glucose-induced toxicity of primary sensory neurons.  
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4.1 Introduction 
Approximately 26 million Americans are afflicted with either Type 1 or Type 2 
diabetes.  Despite the use of insulin and oral anti-diabetic medications to help maintain 
euglycemia, about 60-70% of these individuals develop diabetic peripheral neuropathy 
(DPN)
1
.  To date, approaches toward the treatment of DPN have centered on 
pathways/targets directly limited to hyperglycemia (i.e., polyol & hexosamine pathways, 
advanced glycation end products (AGEs), enhanced oxidative stress, PKC activation)
2
.  
Unfortunately, the contribution of these targets/pathways to the progression of DPN 
differs between individuals and does not occur with biochemical uniformity. 
Consequently, these approaches have resulted in little success for the management of 
DPN.  As an alternative approach, we have explored the pharmacologic modulation of 
molecular chaperones to promote a broad cytoprotective response that may enhance a 
patient’s ability to tolerate hyperglycemic insults and improve the symptoms of DPN.  
Molecular chaperones, such as heat shock proteins 90 and 70 (Hsp90, Hsp70), are 
essential for folding nascent polypeptides into their biologically active structures and for 
the refolding of aggregated and denatured proteins that occur upon cellular stress.
3,4
 
Numerous conditions that cause cell stress can also induce the “heat shock response” 
(HSR); the transcriptional upregulation of antioxidant genes and chaperones such as 
Hsp70. Importantly, small molecule inhibition of Hsp90 is sufficient to induce the HSR. 
KU-32 is a small molecule Hsp90 C-terminal inhibitor that is based on novobiocin, a 
naturally occurring antimicrobial agent that inhibits DNA gyrase (Figure 4-1)
5,6-7
. 
Although the etiology of DPN is unrelated to the accumulation of one specific mis-folded 
or aggregated protein, hyperglycemia is the central mechanism which increase oxidative 
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stress and the oxidative modification of amino acids
8-9
 that impair protein folding
10
, 
decrease mitochondrial protein import
11
 and promote mitochondrial dysfunction
2,8
.  In the 
absence of single, disease-specific protein aggregate, pharmacologic induction of 
cytoprotective molecular chaperones had been shown to improve myelinated and 
unmyelinated fiber function in cellular models of glucotoxic stress and animal models of 
DPN
12
.  Mechanistically, KU-32 is ineffective at preventing neuregulin-induced 
demyelination of myelinated cultures of sensory neurons prepared from Hsp70.1 and 70.3 
double knockout mice, indicating that Hsp70 is necessary for the neuroprotective activity 
manifested by KU-32.  Similarly, weekly treatment with KU-32 restored normal sensory 
and motor nerve function in diabetic wild type mice, but was unable to reverse multiple 
clinical indices of DPN in the diabetic Hsp70 knockout mice
12
.  Collectively, these 
studies provide the biological and clinical rationale to support the modulation of 
molecular chaperones as a viable approach toward the treatment of DPN.  
 
Figure 4-1. Chemical structures of novobiocin and KU-32. 
 
An enviable aspect of KU-32 is that it induces Hsp70 at concentrations well 
below those needed to inhibit Hsp90’s protein folding ability
12
.  Thus, KU-32 possesses a 
rather broad therapeutic window that dissociates cytoprotective properties from 
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potentially cytotoxic effects resulting from the degradation of Hsp90-dependent client 
proteins
13
.  Previous studies have shown that molecules like KU-32, which contain an 
acetamide, manifest neuroprotective properties. However, specific chemical attributes 
that enhance the neuroprotective properties of novobiocin-based analogs were not 
explored
14-15
.  Therefore, we assessed the  neuroprotective efficacy of a series of  
rationally designed novologues in decreasing glucotoxicity induced in primary 
unmyelinated sensory neurons. . 
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4.2 Experimental Methods: 
Preparation of Embryonic Dorsal Root Ganglion (DRG) Neuron Cultures 
DRG from embryonic day 15-18 Sprague Dawley rat pups were harvested into 
Leibovitz’s L15 medium (L15) and dissociated with 0.25% trypsin for 30 min at 37°C.  
The ganglia were sedimented at 1,000 x g for 5 min, resuspended in growth media 
[phenol red free Neurobasal medium (Gibco, Grand Island, NY) containing 25 mM 
glucose, 1X B-27 additive, 50 ng/ml NGF (Harlan Bioscience, Indianapolis, IN), 4 mM 
glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin] and triturated with a fire-
polished glass pipette.  The cells were cultured on collagen-coated (0.1 mg/mL collagen 
followed by overnight air drying in a laminar flow hood) black-walled 96-well plates 
(Corning Incorporated Corning, NY) at a seeding density of 2-3 x 10
4
 cells per well.  
DRG neurons were re-fed the next day with fresh growth media containing 40 μM  
fluorodeoxyuridine and 10 μM cytosine β-D-arabinoside (both from Sigma Aldrich, St. 
Louis, MO) for 2 days to remove proliferating cells.  Experiments were performed on 
DRG neurons on the third day in culture after placing the cells in fresh growth medium.  
Glucotoxicity Assay 
As immature DRG are susceptible to hyperglycemia-induced death
16
, an 
additional 20 mM glucose was added to the growth medium (yielding a total of 45mM 
glucose) for 4 hours.  Preliminary experiments found that 20 mM excess glucose for 4 hrs 
was sufficient to induce a reproducible 40-50% loss in neuronal viability.  As a result, the 
toxicity induced by the acute change in glucose concentration makes it a useful model for 
drug screening
12,17
.  Given the short time frame that the neurons are grown in vitro, 
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they are not pure neuronal cultures but instead, highly enriched.  Importantly, the 
contaminating SCs that remains in the culture are resistant to glucose-induced death as 
we and others have reported previously
16,18
.  Unfortunately, the use of highly purified 
cultures is problematic since the cells extend neurites and establish connections with 
each other, thus becoming resistant to hyperglycemia-induced death
19
. 
DRG neurons were incubated overnight with the novologues in the presence of 
Neurobasal medium, 50 ng/ml NGF and antibiotics only.  In order to monitor the 
efficiency of our the novologues in protecting DRG neurons against glucotoxicity, we 
made use of Calcein AM (Invitrogen, Carlsbad, CA) to measure cell viability. Hydrolysis 
of calcein AM to a fluorescent product can only occur in live cells.  Excess glucose was 
added to the cultures for 4 hrs and cell viability was measured by incubating the cells 
with 2 μM calcein AM for 30 min in the dark at 37°C.  Fluorescence was then measured 
using a plate reader with excitation and emission wavelengths set to 485nm and 520nm, 
respectively.  The arbitrary fluorescence readings were normalized to the total amount of 
protein from each respective well of the neuronal cultures.  The protein concentrations in 
each well were determined using the DC protein assay (Bio-Rad).  Significant differences 
in the efficacy of the novologues for increasing cell viability were determined using a 
Kruskal-Wallis non-parametric ANOVA and Dunn’s post-test.   
Luciferase Reporter Assay and Client Protein Degradation  
A 1.5 kb region upstream of the start codon of the human HSPA1A gene was 
synthesized by GeneArt (Life Technologies, Grand Island, NY) and a 5’ Kpn I and 3’ Sac 
I sites added to direct cloning into the pGL3 basic luciferase reporter plasmid.  DNA 
sequencing verified the integrity of the promoter sequence and the presence of two heat 
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shock elements. 50B11 cells
20
 were grown in 10 cm dishes in DMEM containing 25 mM 
glucose, 10% FCS and 5 µg/ml blasticidin. The cells were transfected using 
lipofectamine and after 24 hr, were re-seeded into 24 well plates at a density of 2 x 10
5
 
cells per well.  The cells were permitted to attach to the plate for 6 hrs in growth medium 
and treated with the indicated concentrations of the various novologues for 16 hr. 
Luciferase activity was assessed and normalized to the total protein concentration of each 
well.  Results shown are from triplicate wells obtained in at least three separate 
experiments.  Preliminary experiments validated that the reporter was strongly activated 
as expected by either heat shock (~ 10 fold) or 250 nM geldanamycin (~4-5 fold).  Client 
protein degradation in MCF7 cells was performed as we have previously described
12
.  
Immunoblot analysis was performed as described
12
 β-
actin were from Stressgen-Enzo Life Sciences (Farmingdale, NY) and Santa Cruz 
Biotechnology (Santa Cruz, CA), respectively. 
Chemistry General.  
All chemical-related spectra and procedures were performed by the Blagg group 
and are  reported in the published version of the manuscript
21
.  
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4.3 Results & Discussion 
Design Rational for Second Generation Novologues 
The Blagg group used molecular modeling and azide-containing novobiocin 
derivatives as photoaffinity probes to elucidate the Hsp90 C-terminal binding site
22
.  Like 
novobiocin, KU-32 (Figure 4-2A) appears in the same docking region and exhibits 
similar binding interactions with both the protein backbone and the amino acid side 
chains of the Hsp90 C-terminal binding site.  However, the coumarin lactone ring of KU-
32 appears too distant from the Lys539 residue to provide any complementary 
interactions and there is a large hydrophobic pocket that could accommodate more 
flexible linkers. Thus, the goals of our chemical-biology undertaking was to create 
structural variants that preserved the necessary attributes for neuroprotection, but add 
modifications that would  explore whether increasing interactions with these regions of 
the protein  may improve neuroprotective efficacy.  Consequently, we designed a novel 
novologue scaffold (Figure 4-2B) where the 3’-carbamate on noviose, that is detrimental 
to Hsp90 inhibitory activity
23
, is omitted while the 7-noviosyl linkage and the requisite 
2’,3’-diol was maintained.  Functionalities were  incorporated onto the 3-aryl substituent 
(B-ring) where it projects into the binding pocket and provides additional hydrophobic 
and hydrogen bonding interactions to complement the scaffold interactions with Lys539.  
A flexible projection of the 4-ethyl acetamide from the A-ring was included to better 
occupy the large hydrophobic pocket (Figure 4-2C) that remains vacant with the 
coumarin ring system of KU-32 (Figure 4-2D).  Based on the novologue design, a library 
based on this generic scaffold was constructed to validate structure-activity relationships 
(SAR) that impart neuroprotection.   
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Figure 4-2. Hsp90 C-terminal binding site and proposed novologue design.  A) KU-
32 docked to Hsp90 C-terminal binding site.  B) Structure of novologue and its attributes.  C) 
Novologue docked to Hsp90 C-terminal binding site.  D) Overlay of KU-32 and novologue 
docked to Hsp90 C-terminal binding site. 
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Based on prior work, phenyl boronic acids containing both electronic and steric 
moieties that could provide crucial interactions with Lys539 and the surrounding pocket 
were chosen for this study.  Towards this goal, phenylboronic acids containing 
electronegative atoms at the meta- and para-positions were used to create a series of 
novologues (Figure 4-3).  In addition, hydrogen bond acceptors were included at these 
locations to provide potential hydrogen bonding interactions with the protonated form of 
Lys539. To test the hypothesis regarding the region surrounding the flexible side chain, 
two cyclohexene analogues 20a–b (Figure 4-4) were also synthesized.  These analogues 
have the same linker length but contain a bulky cyclohexane tether between the biaryl 
ring system and the acetamide to explore interactions with the hydrophobic pocket of 
Hsp90.  Detailed discussion of the novologues synthesis will not be included in this 
dissertation
21
. 
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Figure 4-3. Boronic acids selected for incorporation into novologue X scaffold.  
Hydrophobic groups (2j, 2k) and a tertiary amine (2l) were included as control in this series. 
O
MeO
O
OH
HO
NHAc
R
20a, R = F
20b, R = CF3
 
  
Figure 4-4. Cyclohexene containing novologues. 
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Evaluation of Neuroprotective Efficacy  
Upon synthesis of ethyl acetamide side chain novologues 11a–p that contain 
various substitutions on the B-ring (hydrogen bond acceptors, hydrogen bond donors, 
hydrophobic groups, and a tertiary amine), their neuroprotective efficacy against glucose-
induced toxicity of  embryonic dorsal root ganglion (DRG) sensory neuron cultures was 
evaluated.  As shown in Table 4-1, meta-substituted acetamide novologues (11b, 11e and 
11f) showed significant protection against glucotoxicity and were comparable to that 
observed with KU-32.  Although the corresponding ortho- and para- substituted (11c, 
11d and 11g) derivatives showed significant protection against glucose-induced cell 
death, they were modestly less effective than novologues 11b, 11e and 11f.  However in 
the case of analogues 11i (ortho-OMe) and 11j (meta-OMe) the opposite trend was 
observed.  Electronegative atoms at the meta-position (F, Cl, CF3) exhibited greater 
cytoprotective activity, which is believed to result from favorable interactions with 
Lys539 in the Hsp90 C-terminal binding pocket.  Consistent with this hypothesis, 
increasing the size of the electronegative atom at the meta-position (F to Cl to CF3) 
resulted in a decrease in neuroprotective activity. Similarly, steric bulk was disfavored as 
well.  Analogue 11b (meta-F) was the most cytoprotective (95%±14) compound 
evaluated.  
Electronegative atoms at the ortho- or para-position on ring B (11c, 11d and 11g)  
manifested activities comparable to the unsubstituted analogue (11a) and were less active 
than the corresponding meta-substituted analogues (11b, 11e and 11f).  Although 
novologues 11d and 11g manifested protection against neuronal glucotoxicity, they were 
less effective than KU-32 and 11b.  Hydrogen bond donors at the para-position (11m) 
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appeared to be undesired as 11m (para-OH) was unable to provide significant protection 
against glucotoxicity.  It was also somewhat, but not significantly less protective than the 
unsubstituted analogue (11a). 
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Table 4-1. Cell viability data of ethyl acetamide side chain novologues. 
 
 
 
Entry R1 R2 R3 X Y % of cell 
viability 
a
 
KU-32 - - - - - 86% ± 2 
11a  H H H C C 76%±11
#
 
11b  H F H C C 95%±14
#
 
11c  H H F C C 75%±27
#
 
11d Cl H H C C 71%±21
#,*
 
11e  H Cl H C C 90%±23
#
 
11f  H CF3 H C C 83%±16
#
 
11g H H CF3 C C 74%±19
#,*
 
11h  SMe H H C C 83%±40
#
 
11i  OMe H H C C 92%±10
#
 
11j  H OMe H C C 78%±34
#
 
11k  H Me H C C 82%±30
#
 
11l H CH2-N-
morpholine 
H C C 83%±26
#
 
11m  H H OH C C 67%±10
*
 
11n  H -OCH2O- C C 83%±18
#
 
11o  H H H N C 61%±7
*
 
11p  H H H C N 81%±12
#
 
 
a
In the presence of 1 µM of each novologue + 20 mM excess glucose.  Viability in the presence 
of 20mM excess glucose + DMSO was 54% ± 2. #, p<0.05 versus glucose + DMSO; * p<0.05 
versus glucose + KU-32 (n=6-24) per novologue. 
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On the other hand, hydrogen bond acceptors at the para-position (11c and 11g) 
protected against glucose-induced neuronal death but did not display significantly 
increased protection compared to the novologue containing a para-position hydrogen 
bond donor (11m).  
Pyridine-containing analogues (11o–p) were also synthesized and evaluated for 
neuroprotective activity.  The 3-pyridine analogue (11o) was unable to protect against 
glucose-induce toxicity and was also significantly less protective than the corresponding 
4-pyridine analogue, 11p, KU-32, and the unsubstituted phenyl analogue, 11a.  Although 
the 4-pyridine-containing analogue (11p) demonstrated a modestly improved 
neuroprotective activity when compared to the simple phenyl analogue 11a, this 
difference in efficacy was not significant.  
Neuroprotective activity was also determined for the cyclohexene-containing 
novologues (20a–b) that contain the fluoro or trifluoromethane substituent at the meta-
position of ring B.  In general, cyclohexene-containing analogues 20a-b were less 
efficacious than the corresponding derivatives that contain a flexible side chain (11b 
versus 20a, and 11f versus 20b).  Although not statistically different, novologue 20a 
(meta-F) exhibited slightly better cytoprotective activity than analogue 20b (meta-CF3), 
which follows the same trend observed for flexible acetamide-containing compounds 
(11b versus 11f).  Although these data are inconsistent with our hypothesis that 
accommodation of the hydrophobic pocket would improve efficacy, the cyclohexene ring 
may exceed the space allowed in this binding cleft. 
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Table 4-2. Cell viability data of cyclohexene analogues. 
 
 
Entry R % of cell viability 
a
 
KU-32 - 86% ± 2 
20a  F 78%±18%
#
 
20b  CF3 69%±15% 
#,*
 
 
a
In the presence of 1 µM novologue + 20 mM excess glucose.  Viability in the presence of 20mM 
excess glucose + DMSO was 54% ± 2. #, p<0.05 versus glucose + DMSO; * p<0.05 versus 
glucose + KU-32 (n=8) per novologue. 
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Neuroprotective Activity of Novologues is Dose Dependent 
The data in Table 4-1 clearly support that the majority of novologues synthesized 
decrease neuronal toxicity induced by hyperglycemic stress.  Although some of these 
compounds appear more effective than KU-32 
minor.  Therefore, to further scrutinize their efficacy, compounds exhibiting high 
neuroprotective activity were further evaluated for determination of EC50 values.  Since 
the difference in efficacy for novologues with meta-F and meta-CF3 substitutions on 11b 
and 11f were not significantly different from KU-32 or each other at 1 µM, the EC50 
values for these compounds were determined alongside 11h, 11l, 11n, and 11o.  As 
shown in Figures 4-5A and 5B, EC50 values were significantly improved upon closer 
inspection and clear distinctions were obtained.  Novologue 11b yielded an EC50 value 
(13.0 ± 3.6 nM) that was approximately 14-fold lower than KU-32 (240.2 ± 42.5 nM) or 
11f (187.7 ± 43.5 nM).  Similar results were also observed for novologue 11n, which 
exhibited an EC50 value of 18.4 ± 3.2 nM.  In contrast, novologue 11h which manifested 
similar efficacy to KU-32 at 1 µM, exhibited an EC50 of 384 ± 108 nM, approximately 
1.6-fold greater than KU-32.  
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Figure 4-5. Determination of EC50 of select novologues.  A) DRG sensory neurons 
were incubated in the absence or presence of 0.1-1000 nM of the indicated novologue overnight 
and then subjected to 4 hrs of hyperglycemia.  Cell viability was measured as described in 
Experimental Methods and the data expressed as percent of normoglycemic controls.  Under 
hyperglycemic conditions and in the absence of any novologues, cell viability was 20% ± 7.  B) 
The EC50 was determined using the ECanything function of GraphPad Prism 5.0 and the mean ± 
SEM (n=3-8) is shown. #, p< 0.05 versus KU-32.   
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Novologues Protect Sensory Neurons with Induction of Hsp70  
The data in Figure 4-5 demonstrate that novologues 11b, 11i and 11n are more 
cytoprotective than the initial lead compound, KU-32.  Since we have previously shown 
that the cytoprotective activity manifested by KU-32 requires Hsp70
12
, we determined the 
ability of the novologues to induce Hsp70, relative to KU-32.  To this end, a luciferase 
reporter assay was developed in which the expression of luciferase is driven by the 
human Hsp70 promoter containing two heat shock binding elements
24
.  Since primary 
sensory neurons transfect poorly, an immortalized sensory neuron cell line (50B11 cells) 
was used for transfection
20
.  Importantly, 50B11 cells have a very low basal level of 
Hsp70 expression, similar to primary sensory neurons
7
.  Twenty-four hours after 
transfection with the reporter, cells were re-seeded into 12 well plates and incubated for 
an additional 24 hr.  The cells were then treated for 16 hr with 10–1000 nM of the 
indicated novologues, cell lysates were prepared, luciferase activity assessed and 
luminescence normalized to total protein per well.  Consistent with its increased efficacy 
in protecting against glucotoxicity, 11b was more effective than KU-32 at activation of 
the Hsp70 promoter (Figure 4-6A) and also increased expression of Hsp70 protein at 
lower concentrations relative to KU-32 (Figure 4-6B).  Although 11i had a similar EC50 
as 11b in preventing glucotoxicity, it only activated the Hsp70 promoter at 1 µM and the 
magnitude of this effect was no better than either KU-32 or 11b.  However, it was 
surprising that despite the low EC50 of 11n in protecting against glucotoxicity, 11n did 
not increase luciferase activity at any concentration tested nor did it increase Hsp70 
protein expression as effectively as KU-32 or 11b.  These results suggest that 11n likely 
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affects Hsp70 levels indirectly and that the mechanism for neuroprotection may be 
distinct from that of related novologues.   
Lastly, we mentioned that an attractive property of the modified novobiocin 
scaffold of KU-32 is that it induces Hsp70 at concentrations well below those needed to 
inhibit Hsp90’s protein folding ability
12
.  Therefore, to confirm that this new scaffold 
manifests similar activity, 11b was evaluated against MCF-7 breast cancer cells that are 
highly reliant upon the Hsp90 protein folding machinery.  As can be observed, no client 
protein degradation occurred at concentrations up to 5 µM, indicating the potential for a 
large therapeutic window for this scaffold as well.  
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Figure. 4-6. Induction of Hsp70 by select novologues in the absence of client protein 
degradation.  A) 50B11 cells were transfected with a luciferase reporter whose expression was 
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drive by the human Hsp70 promoter.  The cells were treated with the indicated concentration of 
select novologues for 16 hr and luciferase activity assessed.  **, p < 0.01 and ***, p < 0.001 
versus control; ^, p < 0.05 and ^^^, p< 0.001 versus KU-32 at same concentration.  B) DRG 
sensory neurons were incubated in the presence of DMSO (Cntrl) or 10-1000 nM of the indicated 
novologue overnight and then subjected to 4 hrs of hyperglycemia.  The neurons were harvested 
and Hsp70 and β-actin levels were determined by immunoblot analysis.  Band intensity was 
quantified using Image J, Hsp70 expression was normalized to the level of β-actin and expressed 
as a fold control.  C) MCF7 cells were treated with the indicated concentrations of 11b for 24 hr, 
cell lysates were prepared and the levels of the Hsp90 client proteins, Her2, Raf, and Akt 
determined by immunoblot analysis.  As a positive control, some cells were treated with 500 nM 
geldanamycin (GDA) to induce client protein degradation.  The level of β-actin verified 
equivalent protein loading.  
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4.4 Conclusion 
Using the recently reported model for the Hsp90 C-terminal binding site, a 
novologue scaffold was designed to afford putative interactions with previously 
unoccupied regions of the binding pocket, including Lys539.  Through systematic 
replacement of substituents on the novologue B-ring (see Table 4-2), compound 11b was 
identified as a neuroprotective agent that exhibited ~14-fold greater efficacy against 
glucose-induced toxicity than the lead compound, KU-32.  The concentration of 11b 
needed to manifest neuroprotective activity correlated well with its ability to induce 
Hsp70 levels, and therefore linking cytoprotection to Hsp70 induction.  When combined, 
these data demonstrate the rationally-designed novologue scaffold provides a promising 
platform on which diversification of the B-ring can lead to compounds that exhibit better 
neuroprotective activities.  
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Chapter 5: Future Outlooks & Conclusion  
5.1 Hsp70 Family & Mitochondrial Import 
Mitochondria consist of two membranes, the outer and the inner membrane, and 
two aqueous compartments, the intermembrane space and the matrix.  Although 
mitochondria have their  own genome (mtDNA) in the matrix, 99% of all mitochondrial 
proteins are encoded in the nucleus and cytoplasmically synthesized
1
.  Thus, 
mitochondria require specific mechanisms  (translocases) for precise recognition, 
translocation, and insertion of preproteins both across and into the mitochondrial 
membranes
2
.  Preproteins are usually immature, loosely folded proteins which may lose 
their translocation competence and undergo aggregation or be degraded by cellular 
proteases before import.  To prevent these adverse reactions, preproteins destined for 
mitochondria are guided by molecular chaperones that recognize an N-terminal cleavable 
targeting sequence necessary to direct the proteins to mitochondria
3-5
.  Cytosolic Hsp70 is 
one of the chaperones that binds to the targeting sequences, thereby promoting protein 
recognition and binding onto the mitochondria
6-7
.  Deletion of SSA genes, which encode 
cytosolic Hsp70 in yeast, demonstrated impaired protein translocation into mitochondria 
and preprotein accumulation in the cytosol of the mutant cells
8
.  Translocation of the 
preprotein into the mitochondrial matrix requires two driving forces: the mitochondrial 
membrane potential (ΔΨm) and an ATP-dependent import motor, consisting of 
mitochondrial Hsp70 (mtHsp70), the translocase subunit Tim44, and the co-chaperone 
Mge1
9
.   
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MtHsp70 is another member of the Hsp70 family and has been identified as the 
only ATPase component of the mitochondrial inner membrane import complex
10
.  
Therefore, mtHsp70 is an essential core chaperone for facilitating import, folding 
assembly and degradation of proteins in the mitochondria matrix
2
.  Interestingly, 
mtHsp70 primarily localizes to neurons in the brain, but is observed in glial cells upon 
pathological activation
11
.  Tim44 functions as a membrane anchor for mtHsp70, whereas 
Mge1 is a nucleotide exchange factor that promotes ADP/ATP binding and release in 
mtHsp70
2
.  Knockdown of mtHsp70 in HeLa cells leads to a collapse of ΔΨm, 
accumulation of ROS, decrease of mtDNA copy numbers and alterations in 
mitochondrial morphology under H2O2 stress
12
.  Similar observations were made by 
Baseler et al where cardiac interfibrillar mitochondria isolated from the diabetic animals 
showed decreased ΔΨm and mtHsp70 expression along with impaired mitochondrial 
import
13
.  In contrast, in vivo gene delivery of Tim44, the essential binding partner of 
mtHsp70, showed attenuated oxidative stress and inflammatory responses in diabetic rats 
with increased import of antioxidants such as MnSOD, suggesting that mtHsp70 stability 
is crucial for mitochondria import efficiency
14
.   
5.2 MtHsp70 & Other Cellular Responses 
Besides performing in mitochondrial import, mtHsp70 is also involved in a 
variety of biological functions involved with stress.  Overexpression of mtHsp70 in PC12 
cells lowered ROS production and its accumulation under glucose deprivation suggests 
that mtHsp70 is directly involved in decreasing oxidative stress
15
.  In fact, evidence 
shows mtHsp70 directly interact with the tumor suppressor p53 and the adaptor protein 
p66Shc, both of which are involved in the propagation of pro-apoptotic oxidative stress 
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signals
16
.  P66Shc is a cytoplasmic signal transducer, however, a fraction of p66Shc was 
found localized within the mitochondria where it forms a complex with mtHsp70.  More 
importantly, UV-induced oxidative stress abrogated the mtHsp70-p66Shc interactions, 
leading to a collapse of ΔΨm and cellular apoptosis
17
.  Recruitment of p53 by mtHsp70 
promoted an anti-apoptotic effect in ouabain treated vascular smooth muscle cells by 
deactivating p53 activity
18
.  Moreover, a recent study showed that RelA, a NF-κB family 
member, can translocate into the mitochondria where it interacts with mtHsp70 and 
repress mitochondrial gene expression, oxygen consumption and cellular ATP levels, 
thereby, promoting glycolysis in cancer cells
19
.  This observation may be analogous to 
DPN where activation of PKC induces NF-κB and not only promotes an inflammatory 
response but also contributes to mitochondria energy failure by interacting with mtHsp70.  
Overall, the above studies show that mtHsp70 can serve as a potential, novel therapeutic 
target in the study of hyperglycemia-induced mitochondria dysfunction.   
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5.3 Regulation of mtHsp70 by KU-32 & Its Impact on Mitochondrial 
Function 
In chapter 3, we showed that KU-32 protects neurons from glucotoxicity by 
improving mitochondrial function and decreasing oxidative stress.  Mechanistically, the 
drug efficacy of KU-32 is correlated to cytosolic Hsp70 expression in vivo, however 
increased expression of mtHsp70 has also been reported in hyperglycemically-stressed 
sensory neurons treated with KU-32
20-21
.  Therefore, it is critical to define whether 
functional expression of mtHsp70 is necessary for KU-32-enhanced mitochondrial 
function in sensory neurons under hyperglycemic stress.   
Functional mtHsp70 & Regulation of Mitochondrial Function by KU-32 
In order to study the functional contribution of mtHsp70 to mitochondria activity, 
MKT-077, a rhodacyanine dye that inhibits mtHsp70 by modifying its secondary and 
tertiary structure, was used in preliminary studies
22
.  MKT-077 can impair mitochondrial 
electron transport chain activity in isolated intact mitochondria in a dose dependent 
manner
23
.  Thus, to determine the effect of mtHsp70 inhibition on neuronal mitochondria 
respiration, DRG neurons were cultured in media containing a dose titration of 0.1μM, 
1μM or 3μM of MKT-077 for 48 hours and 1μM KU-32 was given in the final 24 hours.  
Oxygen consumption was assessed using conditions similar to those described in Chapter 
3.  As we reported in Chapter 3, KU-32 increased maximal respiratory capacity (MRC) 
(Figure 5-1A) and MKT-077 concentrations significantly decreased MRC in a dose 
dependent manner.  More importantly, KU-32 may require functional mtHsp70 for its 
neuroprotective efficacy against hyperglycemia-induced mitochondrial dysfunction since 
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MKT-077 blunted the KU-32-induced increase in MRC (Figure 5-1B).  In contrast, 
neurons showed no significant difference in non-mitochondrial respiration when treated 
with rotenone/antimycin cocktail.  These results suggest that functional mtHsp70 is vital 
to mitochondrial but not non-mitochondrial respiration.   
Protein abundance is regulated via modulation of transcription, mRNA stability, 
post-translational modification and turnover.  Control of the timing, location, and amount 
of gene expression can have a profound effect on individual organelle function.  A 
rigorous yet fundamental approach to study transcriptional regulation of mtHsp70 by 
KU-32 is to identify the promoter region which is usually located in the immediate 
vicinity of transcription start site.  KU-32 has been shown to activate the human Hsp70 
promoter which contains two heat shock elements (HSE), which is characterized by an 
array of inverted repeats of the motif nGAAn
24
.  Even though mtHsp70 is uninducible by 
heat, KU-32 may still activate mtHsp70 through the HSE sequence or other previously 
unidentified regulatory regions that may be identified by truncating the promoter 
sequences
15
.  In addition, functional expression of mtHsp70 may also be related to an 
increase mRNA stability or production. Thus, quantitative measures of the mtHsp70 
mRNA level across treatments may serve as another indicator to study the effect of KU-
32 on mtHsp70 gene expression.  
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Figure 5-1.  MKT-077 impairs mitochondrial respiration in a dose dependent 
manner.  Primary DRG neurons were seeded into a 96 well plate and incubated in medium 
containing 25 mM glucose.  The DRG neurons were incubated with MKT-077 at different 
concentration for 48 h and 1 μM KU-32 or DMSO were treated to neurons at the final 24 h.  The 
cells were placed in medium containing 5 mM glucose and 1 mM pyruvate prior to the respiratory 
measures.  (A) Results shown are the mean ± SEM from 3 to 4 wells per treatment from one 
experiment.  Arrows indicate the injection of FCCP and rotenone/ antimycin cocktail.  (B) While 
MKT-077 alone did not induce significant change in MRC at 0.1μM (*, p < 0.01) relative to 
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control neurons, the MRC with KU-32 treatment showed a significant dose-response decrease 
with increased concentration of MKT-077 (
#
, p < 0.001).   
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MKT-077 is a lipophilic cation and this aspect of its structure aids its 
accumulation in mitochondria
24
. However, despite its efficacy in decreasing 
mitochondrial respiration, it may not necessarily be specific for inhibiting mtHsp70.  
Therefore, lentivirus-mediated RNA interference (RNAi) which exerts a powerful and 
unitary knockdown of a target protein was employed.  Preliminary studies using 
lentivirus-mediated knockdown of mtHsp70 expression showed decreased mtHsp70 
expression with an increasing multiplicity of infection (MOI) in primary DRG neurons 
(Figure 5-2). However, mtHsp70 expression was not affected following non-targeting 
shRNA infection or polybrene treatment.  This suggests that RNAi could be employed as 
a target-specific approach to study of the role of mtHsp70 in contributing to the ability of 
KU-32 to improve mitochondrial function.  Given that knockdown of mtHsp70 collapses 
ΔΨm and impairs mitochondrial import, treatment of KU-32 should presumably have no 
impact on either of the indices if KU-32 manifest its efficacy with functional expression 
of mtHsp70
12-13
.  Otherwise, KU-32 may be improving mitochondrial function through 
other regulatory pathways. 
 
Figure 5-2. Targeted knockdown of mtHsp70 using lentivirus-mediate RNA 
interference.  Expression of mtHsp70 in primary DRG neurons was decrease with increased 
MOI titration of lentivrial particles.  
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5.4 Conclusions 
In summary, this dissertation systematically explored two aspects of 
mitochondrial dysfunction in glycemically stress sensory neurons and SCs using an 
unbiased proteomic approach.  First, hyperglycemia alters mitochondrial function and 
these changes are consistent with a potential role of altered bioenergetics in contributing 
to the progression of sensory neuropathy.  Specifically, hyperglycemia decreased the 
level of translation and protein expression of antioxidants and mitochondrial chaperones 
concurrent with an increase in oxidative stress in DRG sensory neurons.  More 
importantly, these are accompanied by a compromised in mitochondrial bioenergetic 
efficiency, a sign of energy failure in DPN.  Of note, despite the lack of superoxide 
production in SCs, its mitochondria bioenergetics are compromised as demonstrated with 
decreased ATP-coupled respiration and increased proton leak.  However, SCs may have 
countered the hyperglycemic stress by increasing its overall mitochondrial protein 
expression including the antioxidant, MnSOD, and shifting the need for ATP production 
from mitochondrial respiration to glycolysis.   
Given that hyperglycemia mediates mitochondrial dysfunction, a second focus of 
this dissertation explored the mechanism of neuroprotection via pharmacological 
induction of molecular chaperones.  As shown in Chapters 3, short term treatment of KU-
32, the novobiocin-derived Hsp90 inhibitor, significantly improved mitochondrial 
function in DRG sensory neurons under hyperglycemic stress by increasing chaperone 
and antioxidant translation, enhancing mitochondrial bioenergetics and decreasing 
superoxide production.  In addition, this dissertation also demonstrates that the 
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neuroprotective efficacy of KU-32 can be enhanced through systematic structural 
modification of its interaction with the Hsp90 C-terminal binding site. 
In the future, it will be important to explore the possibility that molecular 
chaperones may mediate neuronal protection by improving mitochondrial import.  As 
99% of mitochondrial proteins originate from transcription of nuclear genes, their 
transport and import into mitochondria requires both cytosolic and mitochondrial Hsp70 
paralogs.  Emerging data supports that diabetes increases oxidative stress and 
mitochondrial fission/fusion in sensory neurons.  Decreasing oxidative stress and 
maintaining the fidelity of protein import to support this turnover would be essential to 
maximizing the bioenergetic capacity of the organelle.  The ability of KU-32 to increase 
Hsp70 isoforms, decrease oxidative stress and improve mitochondrial bioenergetics 
provides solid rationale that multiple Hsp70 paralogs may improve DPN by functioning 
as chaperones to improve protein import and aid the repair/removal of oxidatively 
damaged proteins within mitochondria.  
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